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SUMMARY  49 
Impaired hepatic glucose and lipid metabolism are hallmarks of type–2 diabetes. 50 
Increased sulfide production or sulfide–donor compounds may beneficially regulate 51 
hepatic metabolism.  Disposal of sulfide through the sulfide oxidation pathway (SOP) is 52 
critical for maintaining sulfide within a safe physiological range. We show that mice 53 
lacking the liver–enriched mitochondrial SOP enzyme thiosulfate sulfur–transferase 54 
(Tst—/— mice) exhibit high circulating sulfide, increased gluconeogenesis, 55 
hypertriglyceridemia and fatty liver. Unexpectedly, hepatic sulfide levels are normal in 56 
Tst—/— mice due to exaggerated induction of sulfide disposal, with an associated 57 
suppression of global protein persulfidation and nuclear respiratory factor–2 target protein 58 
levels. Hepatic proteomic and persulfidomic profiles converge on gluconeogenesis and lipid 59 
metabolism, revealing a selective deficit in medium–chain fatty acid oxidation in Tst—/— mice. 60 
We reveal a critical role for TST in hepatic metabolism that has implications for sulfide-donor 61 




The prevalence of Type 2 diabetes (T2D) continues to soar in parallel with that of obesity 65 
(OMS, 2014). Increased hepatic glucose production and aberrant hepatic lipid metabolism are 66 
cardinal features of T2D (Consoli et al., 1989; Lewis et al., 2002). Dysregulation of hepatic 67 
nutrient metabolism in T2D is a promising area for therapeutic intervention because it 68 
precipitates the more severe liver pathologies that manifest along the spectrum of non-69 
alcoholic fatty liver disease (NAFLD), steatosis, steatohepatitis and hepatocellular carcinoma 70 
(Caron et al., 2011).  71 
Hydrogen sulfide (hereafter referred to as sulfide), an endogenously produced gaseous 72 
signalling molecule (Abe and Kimura, 1996; Wang, 2012; Mishanina, Libiad and Banerjee, 73 
2015; Filipovic et al., 2017), has recently emerged as a modulator of nutrient metabolism 74 
(Desai et al., 2011; Szabo, 2011; Hine et al., 2015; Carter and Morton, 2016).  Enzymatic sulfide 75 
production from sulfur amino acids is catalysed by cystathionine beta–synthase; CBS, and 76 
cystathionine gamma lyase; CTH (Chen, Jhee and Kruger, 2004; Singh et al., 2009) and by 3-77 
mercaptopyruvate sulfur transferase; MPST (Shibuya et al., 2009; Mikami et al., 2011; Yadav 78 
et al., 2013). Thioredoxin-mediated reduction of cysteine persulfides on proteins also 79 
regulates free sulfide and cysteine persulfide levels (Wedmann et al., 2016). Endogenously 80 
produced and exogenously administered sulfide specifically influences hepatic glucose and 81 
lipid metabolism (Mani et al., 2014; Pichette and Gagnon, 2016). Thus, in vitro, treatment of 82 
murine hepatocytes with NaHS, or overexpression of rat Cth in HepG2 liver cells, increased 83 
glucose production through increased gluconeogenesis and reduced glycogen storage (Zhang 84 
et al., 2013).  Conversely, glucose production was lower in hepatocytes from Cth gene 85 
knockout mice (Cth—/— mice) that exhibit low sulfide production (Zhang et al., 2013). Elevation 86 
of sulfide with NaHS administration in vivo reduced cholesterol and triglyceride accumulation 87 
 5 
in the liver of high fat diet (HFD)–fed mice (Wu et al., 2015). In contrast, inter-cross of sulfide 88 
production–deficient Cth—/— mice with the hyperlipidemic Apoe—/— mouse strain (Cth—/—89 
Apoe—/— mice) produced a phenotype of elevated plasma cholesterol following exposure to 90 
an atherogenic diet (Mani et al., 2013). Consistent with their higher cholesterol, Cth—/—Apoe—91 
/— mice developed fatty streak lesions earlier than Apoe—/— mice, and this effect was reversed 92 
by NaHS administration (Mani et al., 2013). Sulfide may also indirectly impact hepatic nutrient 93 
metabolism through its effect on hepatic artery vasorelaxation and thus liver perfusion 94 
(Fiorucci et al., 2005; Distrutti et al., 2008). The apparently beneficial effects of sulfide 95 
administration in multiple disease indications has led to a major drive towards development 96 
of targeted H2S–donor molecules as a therapeutic approach (Whiteman et al., 2011; Sestito 97 
et al., 2017). However, an often-overlooked aspect of net sulfide exposure, key to the efficacy 98 
of therapeutic H2S–donors, is that it is regulated through its oxidative disposal. Thus, 99 
endogenous sulfide exposure is actively limited to prevent mitochondrial respiratory toxicity 100 
(Reiffenstein, 1992; Tiranti et al., 2009; Libiad et al., 2018). Sulfide is rapidly oxidized 101 
(Hildebrandt and Grieshaber, 2008; Norris et al., 2011) through the mitochondrial sulfide 102 
oxidation pathway (SOP), consisting of sulfide quinone oxidoreductase (SQOR), persulfide 103 
dioxygenase (ETHE1/PDO) and thiosulfate sulfurtransferase (TST, also known as rhodanese) 104 
(Hildebrandt and Grieshaber, 2008; Jackson, Melideo and Jorns, 2012; Libiad et al., 2014). The 105 
liver is highly abundant in SOP enzymes, and is a major organ of whole body sulfide disposal 106 
(Norris et al., 2011). Mice lacking the Ethe1 gene (Ethe1—/— mice) die of fatal sulfide toxicity 107 
(Tiranti et al., 2009), consistent with its critical role in sulfide oxidation and the severe 108 
pathological consequences of unchecked sulfide build-up in tissues. However, the importance 109 
of mitochondrial TST in the SOP in vivo remains obscure. In contrast to Ethe1—/— mice, Tst—110 
/— mice were grossly normal despite exhibiting substantially elevated blood sulfide levels, as 111 
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implied by qualitative measures (Morton et al., 2016). This revealed an important yet distinct 112 
role for TST in the SOP in vivo. Nevertheless, Tst—/— mice showed an apparently diabetogenic 113 
impairment of glucose tolerance (Morton et al., 2016), consistent with the concept that 114 
increased sulfide promotes hepatic glucose production (Zhang et al., 2013). As Tst deficiency 115 
represents a model of chronic but viable sulfide elevation, determining the molecular 116 
mechanisms driving their aberrant metabolic profile can provide important insights into the 117 
optimal range for therapeutic sulfide exposure, particularly in light of the current interest in 118 
developing mitochondrially–targeted sulfide–donors (Gero, Domokos Torregrossa et al., 119 
2016; Karwi, Bice and Baxter, 2018). To this end we sought to define the impact of Tst 120 
deficiency on the underlying molecular pathways that impact hepatic metabolism. 121 
  122 
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RESULTS 123 
Tst—/— mice exhibit increased hepatic gluconeogenesis and dyslipidaemia despite mild 124 
peripheral insulin sensitisation.  125 
TST mRNA expression is highest in the liver, http://biogps.org/#goto=genereport&id=22117; 126 
tissue hierarchy of expression was validated in our own mouse substrain (Figure S1A). We 127 
therefore hypothesised that liver TST deficiency was the principal driver of the impaired 128 
glucose tolerance previously observed in Tst—/— mice (Morton et al., 2016). Tst—/— mice 129 
exhibited higher glucose levels than C57BL/6J controls in response to a pyruvate challenge, 130 
consistent with higher hepatic glucose production (Figure 1A). We next tested 131 
phosphoenolpyruvate carboxykinase (PEPCK) activity, a key enzyme of de-novo hepatic 132 
glucose synthesis, and found it was higher in liver homogenates from Tst—/— mice (Figure 1B). 133 
Next, we performed a 1 hour 13C3-pyruvate metabolite–pulse incorporation experiment in 134 
isolated hepatocytes cultured in 12C3-pyruvate–free medium. Hepatocytes from Tst—/— mice 135 
displayed 13C labelling consistent with increased metabolism of pyruvate to oxaloacetate – a 136 
critical early step in gluconeogenesis. Specifically, aspartate, which is derived from pyruvate 137 
via oxaloacetate was significantly increased in the Tst—/— (Figure 1C). A trend towards higher 138 
13C3 malate, and lower 13C2 acetyl–CoA was also observed (Figure S1B and S1C). 13C3 Lactate 139 
was similar between genotypes, suggesting a similar activity of glycolytic disposal of pyruvate 140 
through lactate dehydrogenase (Figure S1B and S1C). Isotopologue distribution is shown in 141 
Fig S1C. Total pool sizes for all measured metabolites were similar between genotypes (Figure 142 
S1D). Although not a direct measure of glucose production, the data from in vitro hepatocytes 143 
suggested skewing of hepatocyte metabolism towards gluconeogenesis, and we therefore 144 
investigated this possibility by further means. Indeed, consistent with increased endogenous 145 
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glucose production in the Tst—/— mice, fasting plasma glucose was higher in Tst—/— mice 146 
relative to 6J mice during the pre-clamp 3-3H glucose tracer infusion phase (60-90 minutes 147 
post tracer) of euglycemic, hyperinsulinemic (EH) clamp experiments (Figure 1D, Table S1A). 148 
Higher plasma glucose levels in Tst—/— mice under these conditions was not explained by 149 
lower glucose utilization in Tst—/— mice; glycogen synthesis and glycolysis were comparable 150 
between genotypes across 60–90 minutes (Table S1A). Glucose turnover – a derived 151 
parameter used to infer glucose production – was also comparable between genotypes (Table 152 
S1A). However, derivation of glucose turnover requires that glucose levels are stable during 153 
the period in which it is calculated. In our pre-clamp baseline period, a highly significant effect 154 
of time (Figure 1D) indicated that this assumption was not met, and thus true endogenous 155 
glucose production cannot be inferred from the glucose turnover parameter in this instance. 156 
Combined with the pyruvate tolerance, PEPCK activity and 13C3-pyruvate pulse data, higher 157 
fasting glucose levels in the Tst—/– mice, given comparable glucose utilization, is most likely 158 
due to higher endogenous glucose production in the Tst—/— mice. 159 
We next wished to explore whether the changes to glucose metabolism were driven by insulin 160 
resistance. Liver glycogen, a marker of long–term carbohydrate storage typically impaired 161 
with insulin resistance, was comparable between Tst—/— and C57BL/6J control mice (Figure 162 
S2A). Despite unchanged steady–state markers of hepatic insulin sensitivity, impaired glucose 163 
tolerance, previously described in the Tst—/— mice (Morton et al., 2016), suggested that whole 164 
body, and usually hepatic, insulin–resistance was present. We investigated this using the 165 
euglycaemic clamp where, unexpectedly, we observed whole–body insulin sensitisation 166 
under these short–term steady–state conditions. During the clamp, when insulin was high, 167 
and blood glucose levels were maintained constant, the glucose infusion rate was comparable 168 
between genotypes (Table S1B). However, an increase in whole–body glucose uptake 169 
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(integral glucose) by tissues in the Tst—/— mice was apparent (Figure 1E, Table S1B), 170 
supporting increased peripheral insulin–sensitivity, with a directionally consistent trend for 171 
increased glucose uptake into several tissues. We confirmed this finding using standard 172 
insulin tolerance tests, where the glucose decrement in response to insulin was greater in 173 
Tst—/— mice (Figure 1F, Figure S2B). Together these data demonstrate a net increase in 174 
dynamic whole–body insulin sensitivity, despite increased hepatic glucose output in Tst—/— 175 
mice. Finally, we assessed whole–body glucose homeostasis with the EH–clamp method after 176 
chronic HFD feeding. Under these conditions, Tst—/— mice maintained increased hepatic 177 
glucose output (Figure 1D) but showed convergence of the insulin–sensitivity profile to that 178 
of the insulin-resistant C57BL/6J mice. 179 
We also assessed whether Tst deficiency was associated with impaired lipid metabolism, 180 
another hallmark of diabetes. Fast protein liquid chromatography analysis of triglyceride 181 
levels and their lipoprotein distribution revealed significantly higher total plasma triglycerides 182 
in Tst—/— mice (Figure 1G). The higher triglyceride was selectively associated with an 183 
increased VLDL triglyceride fraction (Figure 1G), consistent with a dominant liver-driven 184 
impairment in lipid metabolism (Mason, 1998). Total and distinct lipoprotein fraction plasma 185 
cholesterol levels were similar between genotypes (Figure S2C and S2D), suggestive of a 186 
triglyceride–selective effect of Tst deficiency on hepatic lipid efflux. HFD significantly 187 
increased liver lipid content of C57BL/6J mice but did not further increase the elevated lipid 188 
levels in the liver of Tst—/— mice (Figure 1H-1I). 189 
TST deficiency elicits compensatory hepatic sulfide disposal mechanisms that drive reduced 190 
global protein persulfidation.  191 
 10 
A role for TST in the disposal of sulfide was suggested by its participation in the SOP 192 
(Hildebrandt and Grieshaber, 2008; Libiad et al., 2014) and supported in vivo by the 193 
qualitatively higher blood sulfide of Tst—/— mice (Morton et al., 2016), schematically shown in 194 
Figure 2A. Here, we quantified circulating sulfide, showing approximately 10–fold elevation 195 
in the blood and plasma of Tst—/— mice (Table 1A and 1B). Thiosulfate, an oxidised metabolite 196 
of sulfide (Vitvitsky et al., 2015, 2017) and a TST substrate (Banerjee et al., 2015), was 197 
approximately 20–fold higher in plasma (Table 1B), and profoundly higher (450–fold) in urine 198 
(Table 1C) of Tst—/— mice compared to C57Bl/6J mice. Reduced glutathione (GSH) levels were 199 
~2–fold higher in the plasma of Tst—/— mice (Table 1B). To determine any direct hepatic 200 
contribution to the elevated systemic sulfide in vivo, whole blood was sampled from the 201 
inferior vena cava (IVC) (Table 1D). IVC sulfide levels tended to be higher in the Tst—/— mice, 202 
but the magnitude of the increase (~3-fold) did not parallel that in trunk blood (~10-fold), 203 
suggesting liver was not a major source of the elevated circulating sulfide. Surprisingly, liver 204 
homogenate sulfide, thiosulfate, cysteine and GSH levels were similar between Tst—/— and 205 
C57BL/6J mice (Table 1E). Further, cultured hepatocytes from Tst—/— and C57BL/6J mice 206 
exhibited similar intracellular sulfide levels, as estimated using P3, a sulfide–selective 207 
fluorescent probe (Singha et al., 2015) (Table 1F). Mitochondrial sulfide levels in liver reported 208 
by MitoA/MitoN (Arndt et al., 2017) were similarly unchanged between genotypes (Table 1G). 209 
The apparently unaltered hepatic steady-state sulfide levels, despite higher circulating 210 
sulfide, suggested a profound homeostatic mechanism was invoked in the liver of Tst—/— 211 
mice. We assessed respiratory sulfide disposal (antimycin–sensitive) and found this was 212 
markedly increased in hepatocytes from Tst—/— mice, whereas antimycin–insensitive sulfide 213 
disposal was relatively reduced compared to hepatocytes from C57BL/6J mice (Table S2). 214 
Isolated liver mitochondria from Tst—/— hepatocytes also exhibited a higher sulfide disposal 215 
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rate (Table S2). In addition, cysteine and GSH was excreted at higher levels from Tst—/— 216 
hepatocytes under basal conditions and after stimulation of sulfur amino acid metabolism by 217 
addition of methionine (Figure 2B and 2C). Consistent with higher GSH turnover, hepatocytes 218 
from Tst—/— mice showed resistance to exogenous H2O2–mediated mitochondrial ROS 219 
production (Figure S3). We next determined the global hepatic protein persulfidation profile, 220 
the major post–translational modification mediated by sulfide (Krishnan et al., 2011; Kabil, 221 
Motl and Banerjee, 2014; Koike, Nishimoto and Ogasawara, 2017). Mass spectrometry 222 
analysis of maleimide–labelled liver peptides revealed a greater abundance of peptides with 223 
a lower persulfidation level (under-persulfidated) in the liver of Tst—/— mice (Figure 2D). We 224 
confirmed this using semi-quantitative western–blot analysis on pulled down maleimide–225 
labelled proteins (Figure 2E).  Gene Ontology (GO) analysis of under-persulfidated peptides 226 
(20 GO categories; Table 2) showed enrichment for “FAD-binding, methyl transferase, 227 
peroxisome, acyl-CoA dehydrogenase activity and transaminase”. Over-persulfidated 228 
peptides (8 GO categories, Table 2) were predominantly “Nicotinamide metabolism”. 229 
Pathway-specific peptide analysis showed a bias for over-persulfidation in gluconeogenesis 230 
proteins (Figure S4A) and a significantly higher magnitude of change (independent of 231 
direction of change) in persulfidation compared to global persulfidomic changes between 232 
C57BL/6J and Tst–/– mice (Figure S4B).  233 
The hepatic proteome of Tst—/— mice reveals a distinct molecular signature of altered sulfur 234 
and mitochondrial nutrient metabolism.  235 
To gain molecular insight into the mechanisms underlying the apparently diabetogenic 236 
phenotype in Tst—/— mice we compared hepatic proteomes of normal diet (ND)-fed mice. 237 
Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis revealed 4 up–regulated 238 
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pathways in liver of Tst—/— mice related to amino acid metabolism, including sulfur amino 239 
acids, and sulfur metabolism (Table 3A). GO analysis revealed 95 significantly up–regulated 240 
categories in liver of Tst—/— mice (Table S3A). Among the top categories, 7 referred to amino 241 
acid metabolism and 1 referred to the organellar term ‘mitochondrion’. KEGG analysis 242 
revealed 27 down–regulated pathways in the liver of Tst—/— mice (Table 3B) including Phase 243 
1 and 2 detoxification pathways (Cytochrome P450s, Glutathione and Glucuronidation) and 244 
‘Lysosome’, ‘Protein processing in the Endoplasmic reticulum’ organellar terms. 213 GO terms 245 
were significantly down–regulated in Tst—/— mice (Table S4B). Among the most significant 246 
down–regulated terms were phase 2 detoxification ‘glutathione binding’, ‘glutathione 247 
transferase activity’ and ‘endoplasmic reticulum’ categories. We validated broadly consistent 248 
direction of change in a representative subset of proteins (Figures S5A and S5D). The most 249 
robust change we observed was increased MPST protein in whole liver (Figure S5A and S5D) 250 
and mitochondrial sub-fractions (Figure S5B and S5D). This change was remarkable as mRNA 251 
levels for Mpst were lower in Tst—/— mice (Figure S5C), likely as a result of loss of proximal 252 
Mpst promoter function; Mpst is a paralog of Tst (Nagahara, 2011) juxtaposed approximately 253 
1kb from the Tst gene. Protein levels for other sulfide producing and disposal enzymes were 254 
comparable between genotypes (Table S4). A focussed comparison of canonical proteins in 255 
glucose and lipid metabolism pathways (Table S5) revealed four GO categories that were 256 
down–regulated in Tst–/– mice; ‘Lipid metabolic process’, ‘fatty acid beta-oxidation’, ‘Acyl-CoA 257 
dehydrogenase activity’ and ‘Acyl-CoA hydrolase activity’ (Table S5). Canonical insulin–258 
regulated proteins were largely comparable between  genotypes (Table S6).  259 
Hepatic protein expression in Tst—/— mice is consistent with lower NRF2 activation.  260 
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We performed a transcription factor binding site (TFBS) enrichment analysis in the promoters 261 
of proteins that were up–regulated in the liver of Tst—/— mice to look for potential hub 262 
transcriptional drivers of the proteome profile (Figure S6A). This revealed a statistically 263 
significant under-representation of TFBS for the sulfide–responsive (Yang et al., 2013; Xie et 264 
al., 2016) NRF2 transcription factor (Figure S6A). Consistent with reduced hepatic NRF2 265 
activation, 10 out of 47 known NRF2-regulated proteins were lower in the liver of ND-fed Tst–266 
/– mice compared to C57BL/6J (Figure S6B). 267 
Proteome of TST deficiency versus HFD response in C57BL/6J mice reveals distinct regulation 268 
of lipid metabolism, sulfide metabolism and detoxification pathways.  269 
We examined mechanistic commonalities between the diabetogenic hepatic phenotype of 270 
Tst—/— mice and that induced by the diabetogenic HFD–feeding regimen in C57BL/6J mice. 271 
Note, ND-fed Tst—/— mice were in a pre-existing diabetogenic state (Figure 1) that does not 272 
further worsen with HFD (Figure 1H-I, Table S1), suggesting gross phenotypic convergence of 273 
the two genotypes after HFD. We compared the identity and direction of change of the 188 274 
proteins differentially expressed in ND-fed Tst—/— mice (versus ND-fed C57BL/6J mice; Figure 275 
3A) to proteins that were differentially expressed in response to HFD in C57BL/6J mice (432 276 
proteins; Figure 3A). There was a striking 67% overlap in individual proteins (126) in this 277 
comparison (Figure 3A). When we analysed these two protein signatures for directionally 278 
shared pathways, one up-regulated KEGG pathway ‘Glycine, serine and threonine metabolism’ 279 
(Table S7A) and 12 down-regulated KEGG pathways, including ‘drug metabolism’ and 280 
‘endoplasmic reticulum’ (Table S8B) were common to the liver of the ND-fed Tst—/— and HFD-281 
fed C57BL/6J mice. Consistent with a pre-existing HFD–like proteome, the dynamic response 282 
to HFD in the liver of Tst—/— mice was muted, relative to that observed in C57BL6J mice (106 283 
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proteins, a 4–fold lower response; Figure 3B). Focussing on the sulfide pathway, MPST and 284 
SUOX were increased by HFD in C57BL/6J and Tst—/— mice (Table S8). The HFD–induced 285 
increase in MPST was less pronounced in the liver of Tst—/— mice, likely a reflection that it is 286 
already elevated in ND–fed Tst—/— mice. We then considered contrasting, rather than 287 
congruent, proteomic responses arising from TST deficiency versus HFD responses in 288 
C57BL/6J mice to illuminate potential novel pathways underlying the otherwise functionally 289 
similar diabetogenic hepatic Tst—/— phenotype. 5 KEGG pathways (Table S9A) and 4 GO terms 290 
(Table S9B) were oppositely regulated in this comparison. Strikingly, the GO terms were all 291 
related to lipid metabolism, which were up–regulated in the HFD response but down–292 
regulated with TST deficiency (Table S9A-B). An organelle–focussed protein analysis showed 293 
shared up-regulation of mitochondrial and endoplasmic reticulum pathways between TST 294 
deficiency (Figure 3C upper row) and C57BL/6J HFD-responses (Figure 3C lower row), but a 295 
striking discordance in peroxisomal protein pathways (up-regulated by HFD, down-regulated 296 
with TST deficiency) and nuclear proteins (down-regulated by HFD, up-regulated with TST 297 
deficiency; Figure 3C).  298 
The Tst—/— liver proteome and persulfidome converge on transamination and lipid oxidation 299 
pathways.  300 
To assess whether conservation of changes at protein and post-translational modification 301 
levels can illuminate key regulatory hubs driving the hepatic phenotype we ran a congruence 302 
analysis of the proteome and persulfidome. We found that GO categories ‘amino acid’, ‘lipid 303 
metabolism’ and ‘peroxisome’ were significantly regulated at both protein abundance and 304 
persulfidation levels in Tst–/– mice (Table 3C).  305 
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Tst—/— hepatocytes exhibit elevated mitochondrial respiration and a defect in medium–chain 306 
fatty acid oxidation.  307 
Enhanced respiratory sulfide disposal was found from Tst—/— hepatocytes, and enrichment of 308 
mitochondrial proteins was suggested from the liver proteome of the Tst—/— mice (Table S4). 309 
We therefore sought to determine if TST deficiency affected respiratory function and 310 
substrate utilisation of the hepatocyte. Analysis of electron micrographs prepared from the 311 
liver of ND-fed Tst—/— mice and C57BL/6J controls showed morphologically normal 312 
mitochondria (Figure 4A). Basal respiration, comprising ATP–linked and leak respiration, was 313 
significantly higher in hepatocytes from Tst—/— mice (Figure 4B–4D). Maximal hepatocyte 314 
respiratory capacity and non–respiratory oxygen consumption was similar between 315 
genotypes (Figures S7A and S7B). In line with phenotypic convergence following HFD, 316 
hepatocyte respiration was comparable between genotypes from HFD-fed mice (Figures S7C-317 
S7H). A unique feature of the liver from Tst—/— mice was a decrease in proteins and 318 
persulfidation levels of proteins in lipid oxidation pathways. We therefore investigated 319 
hepatocyte respiration of lipids. Using a low pyruvate (100 PM) medium to reveal respiratory 320 
dependency on other substrates, we showed that CPT1A–mediated mitochondrial oxidation 321 
of endogenous long chain fatty acids (LCFA; etomoxir-inhibited) was similar between 322 
genotypes (Figure 4E). Next, we by–passed CPT1A–mediated LCFA transfer, and revealed a 323 
marked deficit in respiration stimulated by the medium chain fatty acid octanoate in 324 
hepatocytes from Tst—/— mice (Figure 4F). A similar experiment adding back pyruvate 325 
revealed comparable stimulation of respiration between genotypes (Figure S7I). In amino acid 326 
free media, combined glutamine–, aspartate– and alanine–stimulated hepatocyte respiration 327 




Elevated TST expression in adipose tissue was recently identified as a genetic mechanism 331 
driving metabolically protective leanness in mice (Morton et al., 2016). Conversely, mice with 332 
genetic deletion of Tst (Tst—/— mice) exhibited impaired glucose tolerance (Morton et al., 333 
2016). However, Tst—/— mice had a subtle adipose tissue phenotype, suggesting a non-334 
adipose origin for impaired glucose homeostasis. We found increased gluconeogenesis, 335 
steatosis and elevated plasma VLDL triglycerides consistent with a predominatly hepatic 336 
origin for the diabetogenic phenoptype. We cannot rule out a contribution of renal 337 
gluconeogenesis to the phenotype, and future work will address this limitation. 338 
Unexpectedly, and in spite of the markedly increased circulating sulfide levels (10-fold), 339 
steady-state sulfide level was normal in the liver of Tst—/— mice. Moreover, we found evidence 340 
for multiple mechanisms for increased hepatic sulfide disposal, reduced downstream sulfide 341 
signalling and associated underlying molecular links to an apparently diabetogenic 342 
phenotype. Our data suggest that the liver of Tst—/— mice has over-shot in its attempt to 343 
maximise hepatic sulfide removal, leading indirectly to detrimental metabolic consequences. 344 
This involves a combination of distinct compartmentalised cellular responses including 345 
increased respiratory sulfide disposal and export of cysteine and GSH. Notably, up-regulation 346 
of translation and recruitment of MPST to the mitochondria of Tst—/— mice is observed. This 347 
response, in face of reduced transcription of Mpst, suggests a powerful post-transcriptional 348 
cellular sulfide sensing mechanism. Interestingly, if MPST is compensating for TST–mediated 349 
sulfide disposal in this context, it implies a subversion of normal MPST function away from 350 
sulfide production (Módis et al., 2013; Szabo et al., 2014; Kimura et al., 2017; Nagahara, 351 
2018). Alternatively this is a response to a perceived lower sulfide environment. TST levels 352 
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were also elevated in the liver of Mpst—/— mice, providing further support for a reciprocal 353 
compensatory mechanism between these two enzymes (Nagahara et al., 2019).  354 
The unexpected finding of normal hepatic sulfide levels in the Tst—/— mice led us to discover 355 
that the metabolic phenotype we observed was driven by the very mechanisms invoked to 356 
maintain sulfide within a normal range rather than sulfide excess per se. Several observations 357 
were consistent with this. For example, the major amino acid pathways increased in the liver 358 
of Tst—/— mice were transaminases involved in metabolism of GSH that support increased 359 
export of sulfur equivalents as GSH (and cysteine). These same transaminases support 360 
gluconeogenesis by redirecting Krebs cycle intermediates (Rui, 2014; Qian et al., 2015; 361 
Sookoian et al., 2016). Re–programming of amino acid metabolism for sulfide disposal with 362 
knock–on effects to drive hepatic glucose production are suggested, rather than any change 363 
to amino acid–linked mitochondrial respiration in hepatocytes. This is supported by the shift 364 
in hepatocyte pyruvate metabolism towards aspartate. In addition, glutathione-S-365 
transferases (GST) that inhibit gluconeogenesis (Ghosh Dastidar et al., 2018) were lower in 366 
the liver of Tst—/— mice. Further, activation of NRF2, which represses gluconeogenesis 367 
(Slocum et al., 2016) appears lower in liver of Tst—/— mice. The involvement of NRF2 in the 368 
Tst–/– liver phenotype is further supported by the phenotype of Nrf2—/— mice that similarly 369 
exhibited steatohepatitis in the absence of insulin resistance (Meakin et al., 2014). However, 370 
we note that NRF2 signalling can be complex and dependent upon dietary context; Nrf2—/— 371 
mice showed improved glucose tolerance after a high fat diet (Zhang et al., 2012) suggesting 372 
any contribution of a NRF2 signalling deficit in the liver of the Tst—/— mice changes upon high 373 
fat feeding. Beyond altered pyruvate flux, we also showed that the hepatocytes of Tst—/— 374 
mice exhibited defective lipid metabolism. Specifically, medium–chain fatty acid (MCFA) 375 
oxidation was impaired, associated with selective reduction of both protein and 376 
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persulfidation levels of lipid catabolic enzymes.  This represents a mechanism linking altered 377 
sulfide metabolism to lipid oxidation, hepatic lipid accumulation and dyslipidaemia. 378 
Consistent with impaired MCFA oxidation defects as one driver of the phenotype, steatosis is 379 
observed in medium–chain acyl-CoA dehydrogenase (Mcad)—/— mice (Tolwani et al., 2005) 380 
and dyslipidemia is found in MCADD deficient humans (Onkenhout et al., 1995). The data we 381 
present adds to a growing understanding of the link between sulfide regulating genes and 382 
nutrient metabolism that has hitherto focussed on the enzymes of sulfide production. 383 
Specifically, we provide support for the importance of the sulfide oxidising pathway as a 384 
regulator of cellular sulfide exposure. Unexpectedly, the data reveal cellular mechanisms that 385 
are engaged to homeostatically regulate sulfide disposal and that can impact upon cell 386 
energetics and nutrient metabolism.  387 
Our findings may have implications for potentially unexpected side effects of sulfide donor 388 
therapeutics. In normal mice, in vivo sulfide administration for 4 weeks post–HFD partially 389 
reversed hepatic lipid accumulation invoked by chronic (16 weeks) HFD (Wu et al., 2015). No 390 
evidence was provided for whether sulfide disposal mechanisms were altered (Wu et al., 391 
2015). This efficacious sub-chronic sulfide administration regimen contrasts with our genetic 392 
model of chronic sulfide elevation as a driver of dysregulated metabolism and NAFLD. Clearly, 393 
the normal mice in the Na2S administration studies had a fully functional SOP, suggesting the 394 
presence of TST is required to achieve the beneficial metabolic effects of Na2S administration. 395 
This is also consistent with the apparently low sulfide signalling status (evidenced by lower 396 
persulfidation, NRF2 target protein abundance) in the liver of the Tst—/— mice. The benefits 397 
of elevated sulfide cannot be realised perhaps because a major mediator of those effects is 398 
missing and the alternate mechanisms invoked do not fully compensate (e.g. MPST), or 399 
actively drive aberrant nutrient metabolism.  Comparable studies of glucose and lipid 400 
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metabolism after manipulation of other sulfide regulating genes are limited. However in a 401 
contrasting model of reduced sulfide production (Cth—/— mice), plasma triglycerides were 402 
lowered (Mani et al., 2013), opposite to what we observed with the Tst—/— mice. The hepatic 403 
sulfide disposal status of the Cth—/— mouse model is unknown, but our findings predict a 404 
suppression of the SOP to spare the limited endogenous sulfide produced. Intriguingly they 405 
also predict a knock-on effect on nutrient homeostasis due to reduced metabolic demand of 406 
the TST/SOP axis. A more direct model informing on the effects of impairment of the sulfide 407 
disposal pathway is deficiency of the key mitochondrial SOP enzyme ETHE1. Ethe1—/— mice 408 
suffer fatal sulfide toxicity (Tiranti et al., 2009) and therefore comparable metabolic studies 409 
are lacking. However, one notable observation is that Ethe1—/— mice have an apparently 10-410 
fold higher liver sulfide exposure than control mice (Tiranti et al., 2009), in contrast to the 411 
normalised hepatic sulfide levels of Tst—/— mice. Circulating sulfide levels were not reported 412 
for comparison, but the presumably relatively lower systemic sulfide levels of Tst—/— mice 413 
appear to have permitted an effective homeostatic sulfide disposal response in the liver to 414 
avoid toxicity, albeit with a metabolic cost. Consequently, the liver of Tst—/— mice has a 415 
distinct functional and proteomic profile to that of the Ethe1—/— mice. For example, in the 416 
liver of Tst—/— and Ethe1—/— mice (Hildebrandt et al., 2013), proteins of the glutathione–S–417 
transferase Mu type (GSTM) and peroxiredoxin (PRDX) families were altered, but sometimes 418 
in the opposite direction or with alteration of distinct protein sub-classes. A notable 419 
difference is also observed in amino acid metabolism. The liver of Ethe1—/— mice exhibited 420 
increased expression of enzymes of branched chain amino acid metabolism (Hildebrandt et 421 
al., 2013), distinct from the predominantly glutathione–related amino acid pathways that are 422 
increased in liver of Tst—/— mice. Beyond sulfide, TST may also have distinct cellular roles that 423 
affect metabolism such as mitoribosomal synthesis, ROS attenuation and modulation of 424 
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mitochondrial iron-sulfur clusters (Bonomi et al., 1977; Pagani and Galante, 1983; Nandi and 425 
Westley, 1998; Nandi, Horowitz and Westley, 2000; Smirnov et al., 2010). 426 
Given the pro-diabetogenic liver phenotype in Tst—/— mice, its was surprising that insulin 427 
signalling in the liver appeared normal and peripheral insulin sensitivity was increased. There 428 
are precedents for increased hepatic glucose production independent of insulin resistance, as 429 
found in the Nrf2—/— mice (Meakin et al., 2014) and as driven by the transcription factor 430 
ChREBP (Uyeda and Repa, 2006; Kim et al., 2016). There is also evidence to support insulin–431 
sensitising effects of sulfide administration in vivo in mice and rats (Feng et al., 2009; Geng et 432 
al., 2013; Xue et al., 2013), consistent with sulfide–mediated insulin–sensitisation of non-433 
hepatic tissues in Tst—/— mice. Higher circulating GSH in Tst—/— mice may also promote 434 
peripheral insulin–sensitisation (Jain et al., 2014; Lutchmansingh et al., 2018). Clearly, the net 435 
balance of glucose production from the liver and its peripheral disposal remains abnormal in 436 
Tst—/— mice. Indeed, the baseline metabolic phenotype of Tst—/— mice resembles in many 437 
ways that of a normal mouse fed a HFD and we showed some overlapping pro-diabetogenic 438 
signatures between the liver proteome of Tst—/— mice and that of HFD-fed C57BL/6J mice. 439 
However, we also found distinct lipid metabolism and peroxisomal protein changes in Tst–/– 440 
mice. Unlike a HFD state, which is associated with dominant hepatic insulin resistance, the 441 
increased hepatic glucose production in ND-fed Tst—/— mice occurs despite normal hepatic 442 
insulin sensitivty. The significant changes in persulfidation of transaminase and 443 
gluconeogenesis proteins suggests coordinated cross–talk across metabolic pathways 444 
underlies this atypical metabolic phenotype. 445 
Sulfide donor therapeutics were proposed as a clinical strategy for improving cardiovascular 446 
health (Szabó et al., 2011; Whiteman et al., 2011; Zhang et al., 2018). Elevated endogenous 447 
sulfide was also implicated in the beneficial metabolic effects of caloric restriction (Miller et 448 
 21 
al., 2005; Hine et al., 2015, 2017, 2018; Shimokawa et al., 2015; Lee, Kaya and Gladyshev, 449 
2016). Our results suggest that chronic sulfide elevation may have unintended detrimental 450 
consequences, driving liver glucose production and fat accumulation to undesirable levels. 451 
This caveat may be fortunately limited to cases where SOP proteins are compromised through 452 
rare genetic effects – such as TST variants (Billaut-Laden et al., 2006; Libiad, Sriraman and 453 
Banerjee, 2015). More broadly, a number of drugs or supplements are known to increase 454 
cyanide, which may dominantly inhibit TST activity and result in secondary sulfide 455 
overexposure. These include nitroprusside (Morris et al., 2017) and amygdalin (Bromley et 456 
al., 2005; O’brien, Quigg and Leong, 2005). Indeed, the TST metabolite thiosulfate is 457 
commonly co-administered with nitroprusside to prevent cyanide toxicity (Curry, Carlton and 458 
Raschke, 1997). Furthermore, dietary and environmental exposure to cyanogenic compounds 459 
(Petrova, 2004), e.g. smoking (Vinnakota et al., 2012) or cyanogenic diets (Kashala-Abotnes 460 
et al., 2019) may interfere with normal TST function and could lead to increased sensitivity to 461 
sulfide therapeutics. In contrast, we have shown that administration of the TST substrate 462 
thiosulfate can ameliorate diabetes (Morton et al., 2016) further underlining the potential 463 
utility of targeting the SOP in metabolic disease. As with all therapeutic strategies, a careful 464 
cost-benefit analysis is required. A comparable case of relevance are the statins, one of the 465 
most potent and widely used drugs to prevent atherosclerosis, which also carry a higher risk 466 
for diabetes (Swerdlow et al., 2015). The full impact of TST manipulation on opposing 467 
metabolic pathways requires further study. Our current study sheds light on the underlying 468 
hepatic mechanisms invoked for sulfide disposal that are relevant to current sulfide–donor 469 
strategies and may inform on routes to reduce their potential metabolic side-effects.  470 
 471 
Limitations of the Study 472 
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Whilst liver is the site of most (~60%) post-absorptive gluconeogenesis in normal animals 473 
within physiological fasting ranges, renal/small intestinal gluconeogenesis begins to 474 
substantially contribute to circulating glucose with prolonged fasting/starvation (Sasaki et al., 475 
2017, Mutel et al., 2011, Mithieux et al., 2003, Stumvoll 1998, Owen 1969). We cannot rule 476 
out a role for renal or intestinal gluconeogenesis in the diabetogenic phenotype of Tst–/– mice. 477 
This will be an important area of future work, although we note that liver TST is at least >3-478 
fold that of kidney and small intestinal TST is very low (BioGPS, Figure S1A). 479 
ACKNOWLEDGEMENTS 480 
This work was funded by a Wellcome Trust New Investigator Award to NMM (100981/Z/13/Z) 481 
and Diabetes UK grant (17/0005697). RCH was funded by a Medical Research Council 482 
Discovery Award (MC-PC-15076). We would like to thank Professor Ken Olsen and Eric DeLeon 483 
(Notre Dame) for advice establishing sulfide measurement by probe.  484 
AUTHOR CONTRIBUTIONS 485 
N.M.M. and R.N.C conceived experiments. R.N.C., M.T.G.G, M. B.-L., A. M.-C., M.L., V.V., B.E., 486 
T. LeB., M.B., S.H., S.G.D., N.Z.M.H., C. Mc F., A.T., N. F., T.G., performed experiments. R.N.C., 487 
M. B.-L., P.F., V.V., T. LeB., N.Z.M.H., T.S., F.B., T.G., R.C.H., B.S., G.G., A.J.F., C.S., R.B. and 488 
N.M.M. analysed and interpreted data and commented on the manuscript. K.H.A., S.S. 489 
generated reagents. C.McM. and R.C.H. generated reagents. R.N.C. and N.M.M. wrote the 490 
manuscript. 491 
Declaration of Interests 492 
The authors have declared that no conflict of interest exists. 493 
 494 
 23 
MAIN FIGURE TITLES AND LEGENDS 495 
Figure 1. Tst deletion results in impaired glucose and lipid metabolism. (A) Plasma glucose over 120 496 
minutes, following pyruvate (i.p., 1.5mg/g) administration in overnight fasted C57Bl/6J (black line, n = 497 
9) and Tst—/— (red line, n = 8) normal diet-fed mice. (B) Extinction of NADH measured by absorbance 498 
at 340nm, coupled to PEPCK activity from liver homogenates taken from C57Bl/6J (white bar, n = 6) 499 
and Tst—/— (red bar, n = 6) normal diet-fed mice. (C) Production of 13C (M+3) aspartate generated after 500 
a 1 hour pulse of 1mM 3-carbon labelled 13C (M+3) pyruvate in 12C pyruvate free media, expressed as 501 
a percentage of the total amount of detected metabolite, in primary hepatocytes from C57Bl/6J (white 502 
bars, n = 6) and Tst—/— (red bars, n = 5) normal diet-fed mice. (D) Blood glucose during the pre-clamp 503 
phase of the hyperinsulinemic, euglycemic clamp from C57Bl/6J (black lines), and Tst—/— (red lines) fed 504 
a control (ND, solid lines, n = 3, 6) or high fat diet (HFD, broken lines, n= 6, 7). (E) Mean integrated 505 
radioactive glucose (inversely related to whole body glucose uptake) during a hyperinsulinemic, 506 
euglycaemic clamp from normal diet fed C57Bl/6J control (white, n = 3), and Tst—/— (red, n = 6) mice. 507 
(F) Plasma glucose expressed as % of baseline glucose, over 120 minutes following insulin (i.p., 1mU/g) 508 
administration in 4 hour fasted C57Bl/6J (black line, n = 8) and Tst—/— (red line, n = 7) normal diet-fed 509 
mice.  (G) HPLC quantified total and VLDL plasma triglyceride in 4 hour fasted C57Bl/6J (white bar, n = 510 
6), and Tst—/— (red bar, n = 6) normal diet-fed mice. (H) Representative light microscopic images of 511 
fixed liver stained with Oil-Red O from normal diet-fed (ND) or high fat diet-fed (HFD) C57Bl/6J and 512 
Tst—/— mice. (I) Analysis of the area of red staining (Oil Red O) after thresholding, using Image J, from 513 
normal diet-fed (no pattern, n = 3-4/genotype) or high fat diet-fed (hatched pattern, n = 4-5/genotype) 514 
C57Bl/6J  (white bars) and Tst—/— (red bars) mice. Data are represented as mean ±SEM. Significance 515 
was calculated using repeated measures ANOVA (A,F) 2-WAY ANOVA (I), 3-WAY repeated measures 516 
ANOVA (D) or unpaired two-tailed student’s t-test (B,C,E,G) * P < 0.05, ** P < 0.01, *** P < 0.001, **** 517 
P < 0.0001. For (D) significant effects of time (****), diet (*) and genotype (*) were found. For (F) the 518 
analysis was performed on absolute glucose values and demonstrated a significant effect of time 519 
(****) and an interaction between time and genotype (*). T-tests revealed that the decrement of 520 
glucose from baseline at 30 and 60 minutes after insulin was greater in the Tst—/— (*). For (I) no main 521 
genotype effect was found, but a significant effect of diet (***), and an interaction (*) were found. 522 
Post Hoc analysis using Sidaks’ multiple comparison test show an effect of diet on the 6J controls (***), 523 
whereas no effect of diet is found on the Tst—/—. See also Fig S1, S2 and Table S1. 524 
 525 
Figure 2. Tst deletion results in increased hepatic sulfur excretion and a reduction of protein 526 
persulfidation. (A) Schematic showing mammalian metabolism of hydrogen sulfide. The canonical 527 
production enzymes are shown in the cytosol; MPST (mercaptopyruvate suflur transferase), CBS 528 
(cystathionine beta synthase), and CTH (cystathionine gammalyase). Mitochondrial oxidation and 529 
disposal of hydrogen sulfide occurs through the ‘sulfide oxidation pathway’, through the actions of 530 
SQOR (sulfide quinone oxidoreductase), ETHE1 (persulfide dioxygenase), TST (thiosulfate 531 
sulfurtransferase), and SUOX (sulphite oxidase). These seven enzymes are widely accepted as major 532 
contributors to intracellular sulfide (and other inorganic sulfur) metabolism. For simplicity, the 533 
diagram does not include sulfide production which can occur within the mitochondria, or disposal 534 
pathways in cytosol. The identity of oxidised sulfur species produced by SQOR remain disputed. The 535 
precise role of TST and other enzymes shown here remains under investigation. (B) Cysteine 536 
concentrations (MBB-HPLC) in the media incubated with primary hepatocytes in the presence 537 
(hatched pattern) or absence (no pattern) of 1mM methionine, from C57Bl/6J (white bars, n = 538 
4/treatment) and Tst—/— (red bars, n = 4/treatment) mice. (C) Glutathione concentrations (MBB-HPLC) 539 
in the media incubated with primary hepatocytes in the presence (hatched pattern) or absence (no 540 
pattern) of 1mM methionine, from C57Bl/6J (white bars, n = 4/treatment) and Tst—/— (red bars, n = 541 
4/treatment) mice. (D) Pie chart depicting the proportion of liver peptides that are significantly higher 542 
(82 peptides, purple space) or lower (311 peptides, yellow space), in their persulfidation rate in the 543 
Tst—/— (n = 3) relative to C57Bl/6J (n = 3) mice. (E) Total DTT-released cysteine-persulfidated liver 544 
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protein as measured by REVERT total protein stain following western blotting, normalised to the total 545 
input protein of the sample from Tst—/— (red bar, n = 4) and C57Bl/6J (white bar, n = 4) mice. Data with 546 
error bars are represented as mean ±SEM. Significance was calculated using 2-WAY ANOVA (B, C) or 547 
student’s t-test (E), * P < 0.05, ** P < 0.01. For (B) and (C) the 2-WAY ANOVA reveals a main effect of 548 
genotype, indicated by * or ** on the histogram. A significant effect of methionine was also found for 549 
both (B) and (C) not indicated on the histogram. For (D) peptides were selected as being significant at 550 
a P-diff of 0.95 or greater. See also Fig S3 and Table S2. 551 
 552 
Figure 3. Tst deletion engenders a high fat feeding–like hepatic proteome with a distinct organellar 553 
signature. (A) Venn diagram representing the number of proteins significantly different (at P < 0.01) 554 
between normal diet-fed Tst—/— and C57Bl/6J (Red circle), and the number of regulated proteins 555 
between high fat fed and normal diet-fed C57Bl/6J (Green circle). The overlap (brown) represents 556 
those proteins regulated in the same direction by both comparisons (n= 4/genotype). (B)  Number of 557 
proteins significantly different (at p < 0.01) between 58% high fat and normal diet in either C57Bl/6J 558 
(white bar), or Tst—/— mice (Red bar), (n= 4/genotype). (C) Pie charts depicting the proportion of 559 
individual liver proteins that are upregulated (Blue space) compared to downregulated (yellow space) 560 
after GO term categorisation according to subcellular location. Upper row; normal diet-fed Tst—/— 561 
relative to normal diet-fed C57Bl/6J. Lower row, high fat-fed C57Bl/6J relative to normal diet-fed 562 
C57Bl/6J. See also Table 3, Figure S5, S6. 563 
 564 
Figure 4. Tst deletion results in increased hepatocyte respiration but impaired medium–chain fat 565 
respiration. (A) Electron microscope images of liver, visualising mitochondria from normal diet-fed 566 
C57Bl/6J (n = 4) or Tst—/— (n = 4) mice. (B) Seahorse trace representing the mean oxygen consumption 567 
rate (OCR), normalised to protein, by hepatocytes from normal diet-fed C57Bl/6J (n = 6) or Tst—/— (n 568 
= 6) mice during a mitochondrial stress test. (C) Respiratory OCR linked to ATP production (oligomycin 569 
sensitive) by hepatocytes from normal diet-fed C57Bl/6J (n = 6) or Tst—/— (n = 6) mice, calculated from 570 
Figure 4B. (D) Respiratory OCR relating to proton leak (oligomycin insensitive) by hepatocytes from 571 
normal diet-fed C57Bl/6J (n = 6) or Tst—/— (n = 6) mice, calculated from Figure 4B. (E) Reduction of 572 
maximal uncoupled respiration following inhibition of long chain fatty acid mitochondrial import using 573 
etomoxir (8 µM), from normal diet-fed C57Bl/6J (n = 4) or Tst—/— (n = 4) mice. (F) Stimulation of 574 
maximal uncoupled respiration following addition of medium chain fatty acid octanoate (250 µM), 575 
from normal diet-fed C57Bl/6J (n = 4) or Tst—/— (n = 4) mice. Data are represented as mean ±SEM. 576 
Significance was calculated using an unpaired two tailed, student’s t-test (C, D, E, F), * P < 0.05. See 577 
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 588 
Table 1. Tst deletion results in altered sulfur metabolites in blood and liver. (A) Sulfide dibimane, 589 
thiosulfate-MBB, measured by fluorescence detection following HPLC, from whole blood taken from 590 
trunk blood of ND-fed C57Bl/6J (n = 4) and Tst—/— (n = 4) mice. (B) Sulfide dibimane, thiosulfate-MBB, 591 
and rGSH-MBB, measured by fluorescence detection following HPLC, from EDTA-Plasma of ND-fed 592 
C57Bl/6J (n = 4) and Tst—/— (n = 4) mice. (C) Thiosulfate-MBB corrected for creatinine from 24 hour 593 
urine samples, taken from ND-fed C57Bl6/J (n = 4) and Tst—/— (n = 5) mice. (D) Sulfide dibimane, and  594 
thiosulfate-MBB, from whole blood taken from the inferior vena cava downstream of the hepatic vein 595 
of ND-fed C57Bl/6J (n = 3) and Tst—/— (n = 3) mice. (E) Sulfide dibimane, thiosulfate-MBB, rGSH-MBB, 596 
and cysteine-MBB from whole liver (n=4/genotype) of ND-fed C57Bl/6J (n = 4) and Tst—/— (n = 4) mice. 597 
(F) Fluorescence from cultured hepatocytes following incubation with P3 (sulfide reactive probe) from 598 
ND-fed C57Bl/6J (n = 4) and Tst—/— (n = 4) mice. (G) Ratio of Mito N/MitoA from the liver of ND-fed 599 
C57Bl/6J (n = 5) and Tst—/— (n = 5) mice. Data are represented as mean ±SEM. Significance was 600 
calculated using unpaired two-tailed student’s t-test. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 601 
0.0001 602 
  603 
Table 1. Sulfur species in blood, urine, tissue and cells 
 C57Bl/6J Tst—/— Tst—/—/6J 
ratio 
Significance 
A Trunk Blood (Micromolar)  
MBB-S (Sulfide) 2.28 +/- 0.43 22.18 +/- 0.85 9.73 **** 
MBB-SSO3 (Thiosulfate) n.d. 6.25 +/- 3.17 n.c. ns 
B Trunk Plasma (Micromolar)     
MBB-S (Sulfide) 1.88 +/- 0.64 24.50 +/- 2.02 13.03 **** 
MBB-SSO3 (Thiosulfate) 3.99 +/- 0.99 80.29 +/- 13.6 20.12 ** 
MBB-GSH (reduced Glutathione) 48.0 +/- 1.15 86.25 +/- 6.27 1.80 *** 
C Urine (Micromoles/creatine/24hrs)     
MBB-SSO3 (Thiosulfate) 4.99 +/- 2.6 2374 +/- 319 475.75 **** 
D Inferior Vena Cava (Micromolar)     
MBB-S (Sulfide) 1.22 +/- 0.20 3.58 +/- 0.87 2.93 ns (0.08) 
MBB-SSO3 (Thiosulfate) 6.58 +/- 4.51 88.3 +/- 13.0 13.42 * 
E Liver (µmoles/kg wet liver)     
MBB-S (Sulfide) 13 +/- 1 17 +/- 3 1.31 ns 
MBB-SSO3 (Thiosulfate) 4 +/- 1 15 +/- 7 3.75 ns 
DNFB-GSH (reduced Glutathione) 6470 +/- 380 6850 +/- 30 1.04 ns 
DNFB-Cysteine (Cysteine) 82 +/- 13 67 +/- 11 0.82 ns 
F Sulfide P3 fluorescence 
(A510nm/protein) 
    
Hepatocyte 7.22 +/- 1.00 7.89 +/- 0.80 1.09 ns 
G Mitochondrial sulfide (MitoA)     
Liver 0.78 +/- 0.16 1.14 +/- 0.45 1.46 ns 
* P < 0.05, ** P < 0.01, *** P < 0.001 **** P < 0.0001  
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Table 2. Tst deletion results in differential persulfidation rate of liver proteins. Significant GO terms 605 
represented by peptides with different persulfidation rates in the ND-fed Tst—/— liver relative to 606 
C57Bl/6J. ‘Direction’ indicates whether the persulfidation is decreased or increased in Tst—/— relative 607 
to C57Bl/6J. ‘Genes’ indicates the number of genes in the Tst—/— that represent the changes driving 608 





Table 2. GO Terms persulfidation rate (Tst—/— vs C57Bl/6J liver, ND-fed) 
GO-ID Name Direction 
 (Tst—/— vs 6J) 
  
Genes 
GO terms Identified by log fold change 
0050660 FAD binding Decreased 12 
0008168 Methyltransferase activity Decreased 9 
9 
 
0016741 Transferase activity, transferring one-carbon groups Decreased 9 
0008565 Protein transporter activity Decreased 8 
0008238 Exopeptidase activity Decreased 7 
0005777 Peroxisome Decreased 7 
0042579 Microbody Decreased 7 
0003995 Acyl-CoA dehydrogenase activity Decreased 6 
0008483 Transaminase activity Decreased 6 
0016769 Transferase activity, transferring nitrogenous groups Decreased 6 
0008757 S-adenosylmethionine-dependent methyltransferase activity Decreased 6 
0016655 Oxidoreductase activity, acting on NADH/NADPH, quinone Decreased 5 
0004177 Aminopeptidase activity Decreased 5 
0000059 Protein import into nucleus, docking Decreased 3 
0005643 Nuclear pore Decreased 3 
0031965 Nuclear membrane Decreased 3 
0044453 Nuclear membrane part Decreased 3 
0046930 Pore complex Decreased 3 
0015629 Actin cytoskeleton Decreased 3 
0016652 Oxidoreductase activity, NADH/NADPH, NAD/NADP acceptor Decreased 3 







0016651 Oxidoreductase activity, NADH/NADPH, Increased 5 
0003954 NADH dehydrogenase activity Increased 4 
0008137 NADH dehydrogenase (ubiquinone) activity Increased 4 
0050136 NADH dehydrogenase (quinone) activity Increased 4 
0006739 NADP metabolism Increased 3 
0006769 Nicotinamide metabolism Increased 3 









Table 3. KEGG and GO changes (Tst—/— vs C57Bl/6J liver, ND-fed)  
Entry Name Genes Significance 
A. KEGG pathways Increased in ND Tst—/— liver  
00250 Alanine, aspartate and glutamate metabolism 6 *** 
00260 Glycine, serine and threonine metabolism 5 ** 
00270 Cysteine and methionine metabolism 4 * 
04122 Sulfur relay system 2 * 
B. KEGG Pathways Reduced in ND Tst—/— liver  
00980 Metabolism of xenobiotics by cytochrome P450 12 **** 
00982 Drug metabolism – cytochrome P450 12 **** 
05204 Chemical carcinogenesis 12 **** 
00480 Glutathione metabolism 8 *** 
00040 Pentose and glucoronate interconversions 5 ** 
04142 Lysosome 6 ** 
04390 Hippo signalling pathway 4 ** 
00500 Starch and sucrose metabolism 5 ** 
05215 Prostate cancer 3 ** 
 
 
04024 cAMP signalling pathway 4 * 
04141 Protein processing in ER 9 * 
05211 Renal cell carcinoma 3 * 
00830 Retinol metabolism 6 * 
00053 Ascorbate and aldarate metabolism 4 * 
00860 Porphyrin and chlorophyll metabolism 4 * 
04722 Neurotrophin signalling pathway 3 * 
04670 Leukocyte transendothelial migration 4 * 
04010 MAPK signalling pathway 4 * 
04720 Long-term potentiation 2 * 
04914 Progesterone-mediated oocyte maturation 2 * 
04062 Chemokine signalling pathway 3 * 
04110 Cell cycle 3 * 
04015 Rap1 signaling pathway 4 * 
00983 Drug metabolism - other enzymes 5 * 
04918 Thyroid hormone synthesis 3 * 
04612 Antigen processing and presentation 3 * 
05203 Viral carcinogenesis 5 * 
C. GO terms common to Persulfidome and Proteome in ND Tst—/— liver 
GO-ID Name of GO term Persulfidation 
(Tst—/—  vs 6J) 
Abundance 
(Tst—/—  vs 6J) 
0008483 Transaminase activity Decreased  Increased 
0016769 Transferase activity, transferring nitrogenous groups Decreased  Increased 
0003995 Acyl-CoA dehydrogenase activity Decreased Decreased 
0005777 Peroxisome Decreased Decreased 
0042579 Microbody Decreased Decreased 
* P < 0.05, ** P < 0.01, *** P < 0.001 **** P < 0.0001  
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Table 3. Protein abundance and persulfidation in ND-fed Tst—/— liver. (A) Significant KEGG pathway 617 
terms represented by proteins that are more abundant in the liver of ND-fed Tst—/— compared with 618 
ND-fed C57Bl/6J. (B) Significant KEGG pathway terms represented by proteins that are less abundant 619 
in the liver of ND-fed Tst—/—compared with ND-fed C57Bl/6J. ‘Genes’ indicates the number of genes 620 
in the Tst—/— that represent the changes driving the KEGG pathway. (C) GO terms that are significantly 621 
regulated at both the level of cysteine persulfidation and protein abundance in liver of ND-fed Tst—/—622 
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STAR       METHODS 644 
RESOURCE AVAILABILITY   645 
 646 
Lead contact 647 
Further information and requests for resources and reagents should be directed to and will 648 
be fulfilled by the lead contact, Nicholas M. Morton (nik.morton@ed.ac.uk). 649 
 650 
Materials availability 651 
No other new unique reagents were generated for the production of the data in this paper. 652 
 653 
Data and code availability 654 
Proteomics and persulfidomics root data from the iTraq and persulfidated peptide mass 655 
spectrometry experiments have been deposited to the ProteomeXchange Consortium via the 656 
PRIDE (Perez-Riverol et al., 2019) partner repository with the dataset identifier PXD028909. 657 
This paper does not report original code. 658 
Any additional information required to reanalyse the data reported in this paper is available 659 
from the lead contact upon request. 660 
 661 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 662 
Experimental animals. All experiments were performed according to guidelines set out by 663 
the ethical committees of The University of Edinburgh and Physiogenex S.A.S, Prologue 664 
Biotech, Labѐge, FRANCE. Experiments were carried out within the framework of the Animals 665 
(Scientific Procedures) Act (1986) of the United Kingdom Home Office or related laws from 666 
the European Union (France). In all studies, animals within genotype cohorts were randomly 667 
assigned to diet or intervention groups. All animals were maintained in standard housing with 668 
12 hour light and 12 hour dark cycles (7 a.m. to 7 p.m.) and ad libitum access to the 669 
appropriate diet. For in vivo experiments (pyruvate tolerance test, insulin tolerance test, 670 
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euglycaemic clamps), operators and animal handlers were blinded to the data, which was 671 
generated by a second individual who was blinded to the treatment regimen until the code 672 
was broken. All of the studies used male mice housed in cages of 3-6 individual littermates 673 
until intervention. The mice for this study originated from C57Bl/6N Tst—/— mice (Morton et 674 
al., 2016) backcrossed onto the C57Bl/6J genetic background for >10 generations. Mice were 675 
placed onto high fat diet D12331, (58% calories from fat, Research Diets, New Brunswick, 676 
USA) from between 6-8 weeks of age, for 6-7 weeks prior to testing, and compared to mice 677 
maintained on standard low fat diets, RM1 or D12383 (low-fat high-cornstarch, Research 678 
Diets, New Brunswick, USA). 679 
Hepatocyte preparations. Mice were killed by CO2 asphyxiation, followed by cervical 680 
dislocation. The chest cavity was opened, the portal vein was cut and the thoracic vena cava 681 
was cannulated via the right atrium. The liver was perfused with (37°C) perfusion media (140 682 
mM NaCl, 2.6 mM KCl, 0.28 mM Na2HPO4, 5 mM glucose, 10 mM HEPES, 0.5 mM EGTA, pH 683 
7.4), 6 mls/min for 10 min. The liver was then perfused with digestion media (perfusion media, 684 
without EGTA, including 5 mM CaCl2, and 100 U/ml collagenase type 1) for 5-7 min. Finally, 685 
the liver was perfused with perfusion media for a further 10 min. Cells were extruded from 686 
liver into DMEM medium (DMEM, 5.5 mM glucose, 10% FCS, 7 mM glutamine, and 687 
penicillin/streptomycin antibiotics), and then passed through a 40 micron filter. Cells were 688 
spun twice and washed with medium, at 500 rpm (47 g) for 5 min. Cells were spun through a 689 
50% Percoll pH 8.5-9.5/DMEM solution at 1000 rpm (190 g) for 15 min to remove dead cells 690 
and non hepatocytic liver cell types. Hepatocytes collected in the pellet fractions were 691 
resuspended in medium and spun twice with washing at 500 rpm (47 g) 5 minutes. Yields and 692 
viability were assessed by counting using a haemocytometer, and proportion of trypan blue 693 
exclusion respectively.  Yields ranged from between 2 x 106 – 1.5 x 107 viable cells, and viability 694 
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was above 85%. Unless otherwise stated, hepatocytes were seeded onto collagen coated 695 
tissue culture plastic (collagen from rat tails, Sigma), and maintained in DMEM with 5.5 mM 696 
glucose, 10% FCS, 7 mM glutamine, and antibiotics). 697 
 698 
METHOD DETAILS 699 
 700 
Pyruvate tolerance test. Blood glucose was measured from 16 hour fasted mice before (0 701 
time) and following bolus sodium pyruvate administration (i.p. 1.5 mg/g bodyweight). Blood 702 
was collected following tail venesection at 0, 15, 30, 60 and 120 minutes after injection. 703 
Glucose was measured from blood using a Glucometer (OneTouch, Lifescan, Milpitas, USA or 704 
Accu-Chek, Performa nano, Roche).  705 
PEPCK activity assay. Activity of phosphoenolpyruvate carboxykinase was measured from 706 
cytosol samples obtained from frozen liver. Samples were homogenised in 250 mM sucrose, 707 
5 mM HEPES, pH 7.4. and centrifuged at 4°C, 12,000 rpm (17,390 g) for 15 min. Supernatants 708 
were ultracentrifuged at 4° C, 60,000 rpm (289,000 g) for 30 min. Activity of PEPCK from 709 
cytosolic fractions was inferred in this assay from NADH extinction, linked to the conversion 710 
of phosphoenol pyruvate into oxaloacetate in the presence of carbonate, dGDP and MnCl2, 711 
and the subsequent conversion of oxaloacetate into malate by adding malate dehydrogenase. 712 
Baseline measurements at 340 nM (NADH) were taken for 20 min before adding phosphoenol 713 
pyruvate, and the reaction proper was initiated with dGDP. The reaction was then measured 714 
for a further 40 min. 715 
13C Pyruvate metabolite tracing. After overnight culture on collagen coated 6-well tissue 716 
culture plates, hepatocytes were incubated with 1 mM 13C3 labelled pyruvate in serum free 717 
DMEM for 60 min. Metabolites were extracted by washing individual wells with ice-cold PBS 718 
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and addition of cold extraction buffer (50% methanol, 30% acetonitrile, 20% water solution 719 
at -20°C or lower). Extracts were clarified and stored at -80°C until required. LC-MS was 720 
carried out using a 100 mm x 4.6 mm ZIC-pHILIC column (Merck-Millipore) using a Thermo 721 
Ultimate 3000 HPLC inline with a Q Exactive mass spectrometer. A 32 min gradient was 722 
developed over the column from 10% buffer A (20 mM ammonium carbonate), 90% buffer B 723 
(acetonitrile) to 95% buffer A, 5% buffer B. 10 μl of metabolite extract was applied to the 724 
column equilibrated in 5% buffer A, 95% buffer B. Q Exactive data were acquired with polarity 725 
switching and standard ESI source and spectrometer settings were applied (typical scan range 726 
75-1050). Metabolites were identified based upon m/z values and retention time matching 727 
to standards. 728 
Plasma lipid analysis. Mice were fasted with free access to water for 4 hours prior to cull by 729 
decapitation or pentobarbital euthanasia. Trunk blood (decapitation) was collected directly 730 
into Sarstedt Microvette CB 300 K2E EGTA containing plasma sample tubes (Sarstedt, 731 
Nümbrecht, Germany). Venous blood from the abdominal vena cava (post euthanisation) was 732 
collected into a BD Plastipak 1 ml syringe (BD, Madrid, Spain). This was then transferred to 733 
Sarstedt EGTA containing sample tubes for centrifugation. Blood samples obtained by either 734 
method were centrifuged at 20oC and 5000 rpm (2655 g) for 5 min to obtain plasma samples. 735 
Plasma samples were analysed for cholesterol and triglyceride content by as previously 736 
described (Peters et al., 1997). Briefly, samples were subjected to gel filtration 737 
chromatography using an integrated Alliance HPLC separations module (e2695, Waters, 738 
Milford, US) to separate lipoproteins based on size. Effluent was immediately and 739 
continuously mixed with either triglyceride (Infinity Triglyceride, Thermo Scientific, 740 
Loughborough, UK) or cholesterol (Infinity Cholesterol, Thermo Scientific, Loughborough, UK) 741 
enzymatic colourmetric detection kits at the correct conditions for reaction (as specified in 742 
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manufacturer’s guidance). The optical density was then recorded using a spectrophotometer 743 
at the appropriate wavelength and the signal turned into a continuous trace i.e. a lipid profile. 744 
By identification of the lipoprotein peaks (based on their time of emergence from the 745 
chromatograph) the concentration for each could be calculated. 746 
Oil Red-O lipid analysis of liver. 5 µm cryostat cut frozen sections of liver were collected onto 747 
Superfrost slides (Thermo), and rinsed with 60% isopropanol. Slides were incubated in freshly 748 
prepared staining solution (2.1 mg/ml Oil Red O in 40% isopropanol/water) for 10 – 30 min 749 
and rinsed with 60% isopropanol. Slides for representative images were counterstained for 750 
nuclei in haematoxylin (Harris) for 1 minute. For image analysis, slides were not 751 
counterstained. All slides were then rinsed in running tap water for 2 min, before mounting. 752 
Sections were captured using an AxioScan Z1 slide scanner at ×20 magnification and analysis 753 
of the proportional area of Oil Red O staining (area of stain/unit area of section) was 754 
performed using ImageJ software (National Institutes of Health), assessed by a blinded 755 
assessor. 756 
Liver Glycogen measurement. Frozen liver samples (between 30-90 mg) were heated to 757 
100°C in an Eppendorf tube with 0.3 mls of 30% KOH for 30 min with vigorous shaking at 10-758 
min intervals. Samples were heated for a further 2-3 min after addition of 0.1 ml 1M Na2SO4 759 
and 0.8 ml ethanol. Samples were then centrifuged at 4°C at 1011 g for 5 minutes. The 760 
supernatant was removed, and the pellet resuspended in distilled H2O before 0.1 ml 1M 761 
Na2SO4 and 0.8 ml ethanol were again added, and samples boiled at 100°C for 5 min before 762 
centrifugation. This was repeated a final time to wash the sample. The pellet was resuspended 763 
in a 10 mg/ml (~1200 U/ml) amyloglucosidase enzyme in 0.3 M sodium acetate (pH 4.8). 764 
Samples were then incubated at 50°C for 2 hours. Quantification of samples was then 765 
performed using a standard hexokinase based glucose assay (Glucose (HK) Assay Kit, Sigma, 766 
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GAHK20). The assay was performed following manufacturer’s instructions and values 767 
calculated by extrapolation from a standard curve after measuring absorbance using a plate 768 
spectrophotometer (Molecular Devices OPTImax microplate reader and software, Molecular 769 
Devices, Wokingham, UK). 770 
Western blotting for protein abundance. Frozen liver samples (stored -80°C) from mice were 771 
homogenized in protein lysis buffer (50 mM Tris, 270 mM sucrose, 50 mM NaF, 1 mM EDTA, 772 
1 mM EGTA, 1% Triton X-100, 10 mM B-glycerophosphate, 5 mM Na Pyrophosphate, 1 mM 773 
orthovanadate, 0.1% β-Mercaptoethanol, 1 tablet protease inhibitor cocktail inhibitor, pH 774 
7.4, all Sigma Aldritch). Samples were then centrifuged at 13,200 rpm (18500 g) for 15 min at 775 
4°C and the supernatants aliquoted and stored at -80°C. Protein samples were loaded onto 776 
10% acrylamide/bis-acrylamide gels (30% acrylamide, Sigma Aldritch) and separated by 777 
electrophoresis. A coloured molecular weight marker was also run on all gels (Full range 778 
rainbow molecular weight markers, GE Healthcare). Gels were transferred overnight using a 779 
Bio Rad wet transfer system onto Amersham Hybond – P membranes (GE Healthcare). After 780 
transfer, for normalisation of specific targets to total protein, membranes were stained using 781 
the REVERT total protein stain (LICOR), according to manufacturers’ instruction. Following 782 
stain and wash, lanes of each sample were analysed using a LI-COR Odyssey scanner (700nm 783 
channel). For blots using a house keeping protein for normalisation, the total protein stain 784 
was not performed, and membranes were transferred directly to blocking. All membranes 785 
were blocked in Tris buffered saline with 0.01% tween (TBST, containing 5% skimmed milk 786 
powder (Marvel skimmed milk powder) for 1 hour and then rinsed in TBST. Blocked 787 
membranes were then incubated with the appropriate primary antibody in TBST containing 788 
5% BSA (Sigma Aldritch) overnight at 4°C. Following three 5 min washes with TBST, secondary 789 
antibody incubation for all blots was with an appropriate green or red fluorescent antibody, 790 
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incubated at room temperature for 2 hours in TBST containing 5% BSA. Membranes were 791 
washed three times in TBST then scanned using the LI-COR Odyssey scanner. Odyssey 792 
software (LI-COR Biosciences) was used to quantify band intensity.  For normalization to a 793 
house keeping protein, the individual band intensity of B-actin was used for each sample. 794 
Primary antibodies used were; TST, Rabbit, GeneTex, GTX114858, MPST, Rabbit, Abcam, 795 
Ab224043, GOT1, Rabbit, Abcam, ab170950, GSTT1, Rabbit, Proteintech, 15838-1-AP, 796 
MAT1A, Rabbit, Abcam, ab129176, BHMT Rabbit, Proteintech, 15965-1-AP, CSAD, Rabbit, 797 
Abcam, ab91016, PPCS Rabbit, Atlas Antibodies, HPA031361. Secondary antibodies used 798 
were; IRDye800CW Goat anti-Rabbit, Li-Cor, 926-32211, IRDye 680RD Donkey anti-Mouse, Li-799 
Cor, 926-68072. For normalisation B-Actin, Mouse, Abcam, ab8226 was used for whole tissue, 800 
and Cox IV (mitochondrial loading control), Abcam, ab16056 was used for mitochondrial 801 
fractions.  802 
Insulin tolerance test. Male C57BL/6J or Tst—/— mice were maintained on standard chow 803 
(RM1). Mice were fasted for 4 hours prior to injection i.p. of insulin (1 mU/g bodyweight, 804 
NovoRapid 100U/ml, Novo Nordisk). Tail venesection blood samples were taken prior to, and 805 
15, 30, 60 and 120 minutes post injection. Blood glucose was measured from samples using a 806 
Glucometer (Accu-Check, Performa Nano, Roche). Blood glucose was plotted across time to 807 
evaluate net glucose accumulation in blood. 808 
Euglycemic hyperinsulinemic clamps. Male C57BL/6J or Tst—/— mice were maintained on 809 
standard diet (RM1 (E) 801492, SDS) or high fat diet for 6 weeks (58% fat, D12331, Research 810 
Diets). Prior to performing the hyperinsulinemic euglycemic clamp an indwelling catheter was 811 
placed into the femoral vein under isoflurane anesthesia, sealed under the back skin, and 812 
glued onto the top of the skull. Clamps were performed 5-6 days after recovery from 813 
catheterization. Mice were fasted 6 hours prior to a basal blood sample was taken for glucose 814 
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and insulin. Mice then received a bolus of D-[3-3H] glucose (30 µCi) and perfused with 3H-815 
glucose (30 µCi/kg/min at 2 µl/min) for 210 min (which covers the basal phase and 816 
hyperinsulinemic clamp). At steady state (60 min after start of perfusion), 5 µl of blood was 817 
collected and glycemia measured from tail tip every 10 min over 30 min for 3H-radioactivity 818 
analysis for determination of whole body glucose turnover glycolysis and glycogen synthesis 819 
rate in the basal state. 90 min after start of perfusion, the hyperinsulinemic clamp starts by 820 
co-perfusion with insulin 8 mU/kg/min for the clamped phase over 120 min. Blood glucose 821 
was assessed every 10 minutes, and glucose infusion adjusted until steady state blood glucose 822 
(120 mg/dl +/- 10 mg/dl) was achieved. 5 µl of blood was collected from, tail tip every 10 min 823 
for 3H- radioactivity analysis. At 150 min after the start of perfusion, a bolus of 14C-2-824 
deoxyglucose (25 µCi) was perfused to evaluate tissue specific uptake. At the end of the 825 
perfusion (210 min), blood is collected from the retro-orbital sinus to measure plasma insulin 826 
and mice sacrificed by i.v. injection of pentobarbital and cervical dislocation. Tissues (Inguinal 827 
WAT, Epididymal WAT, Soleus muscle, Extensor digitorum longus muscle, Vastus lateralis 828 
muscle, Tibialis anterior muscle, Heart apex, Liver) were removed by dissection and flash 829 
frozen in liquid nitrogen (stored -80°C until measured). Tracers were used to calculate various 830 
aspects of glucose metabolism (Altszuler et al., 1956; Carter and Morton, 2016). Parameters 831 
measured or calculated include body weight, glucose infusion rate, whole body turnover, 832 
hepatic glucose production, whole body glycolytic rate, whole body glycogen synthesis rate, 833 
and tissue glucose utilization.  834 
MBB derivatization of whole blood and plasma. Whole blood was taken after cull of mice, 835 
from trunk (following decapitation), or portal vein (following CO2 euthanasia). EDTA-plasma 836 
was obtained from trunk blood following decapitation and collected onto ice. Blood for 837 
plasma was centrifuged within 15 min of collection for 5 min at 5000 rpm (2655 g) at 4°C.  838 
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Blood and plasma samples (15-50 µl) were derivatized with monobromobimane by addition 839 
of 200 μL of 80 mM EPPS (4-(2-Hydroxyethyl)-1-piperazine propanesulfonic acid, 8 mM DTPA 840 
(diethylenetriaminepentaacetic acid) pH 8.0, 50% acetonitrile, 2.3 mM monobromobimane. 841 
Reaction vials were capped tightly and vortexed for 1 minute and incubated protected from 842 
light at room temperature for 30 min. 1 mL ethyl acetate was added, the tube capped and 843 
vortexed for 1 min and incubated protected from light for 10 min. The reaction vials were 844 
centrifuged at 1800 rpm (350 g) for 7 min to separate aqueous and organic layers. The organic 845 
layer was collected from each extraction, transferred to a 1.5 mL brown glass vial and the 846 
solvent was evaporated completely under a nitrogen stream. Acetonitrile (200 μL) was added 847 
to each vial, and the solvent was again evaporated to remove any traces of ethyl acetate. 848 
Dried MBB-derivatives were stored at -20°C until analysed. 849 
Fluorometric quantification of MBB-sulfur species. MBB-sulfur species (sulfide, thiosulfate, 850 
reduced glutathione, and cysteine) in samples was quantified by HPLC separation and 851 
detection with a fluorescence detector. The dried MBB derivatives were re-suspended in 50 852 
μL of Buffer A (10 mM tetrabutylammonium phosphate aqueous, 10% methanol, 45 mM 853 
acetic acid adjusted to pH 3.4). The entire sample was transferred to an HPLC autosampler 854 
vial with a 200 μL glass sample insert, and the vial was closed with a penetrable cap. 20 μL of 855 
the sample was injected onto a C8 reverse-phase column (LiChrospher 60 RP-select B 5 μm 856 
4.0 × 125 mm LiChroCART 125-4, Merck KGaA) and a guard column (LiChroCART 10-2, 857 
Superspher 60 RP-select B cartridge) on an Ultimate 3000 UHPLC+ focused system (Thermo 858 
Scientific). MBB derivatives were eluted with a linear gradient from 10% buffer B (10 mM 859 
tetrabutylammonium phosphate in methanol, 10% water, 45 mM acetic acid) to 100% buffer 860 
B over 30 min. The eluent was analysed by fluorescence (λex = 380 nm, λem = 480 nm). 861 
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Sulfur metabolite analysis from liver. Livers from mice were removed promptly following 862 
decapitation (within 2 min), and frozen on powdered dry ice. Frozen tissue was pulverized 863 
and derivatized with either 2,4-dinitrofluorobenzene for detecting GSH or 864 
monobromobimane for detecting sulfide and thiosulfate as described previously (Mosharov, 865 
Cranford and Banerjee, 2000; Vitvitsky et al., 2006, 2015).  866 
P3 fluorescence detection of sulfide in hepatocytes. Hepatocytes were seeded in glass 867 
bottomed, collagen coated wells (0.75 cm2, 12,500 hepatocytes per well) and cultured in 868 
DMEM with 5.5 mM glucose, 10% FCS, 4 mM glutamax or 7 mM glutamine, and antibiotics 869 
overnight. P3 H2S reactive probe (Singha et al., 2015) was added to wells at 10 µM in serum 870 
free DMEM for 30 min, prior to gentle washing with Krebs phosphate buffered saline (pH 7.4). 871 
Plates were measured using the TECAN fluorescence plate reader, following excitation at 375 872 
nm and detection at 510 nm. No-cell control wells were used for subtracting from the cell 873 
containing values. Corrected fluorescence emission data was normalised to protein as 874 
estimated by sulforhodamine dye. Briefly, after the run cells were fixed with 10% 875 
trichloroacetic acid overnight at 4°C. Cells were washed 9 times with tap water, and air dried. 876 
Cells were incubated with 200 μl of 0.4% Sulforhodamine dye/1% acetic acid for 1 hour at 877 
room temperature. Stain was removed, and washed 4 times with 1% acetic acid, and then air 878 
dried. Stain was dissolved in 200 μl of 10 mM Tris pH 10.5 for 30 min, and 100 μl was measured 879 
by colorimetric absorbance spectroscopy at 540 nm. After subtracting a baseline absorbance 880 
from blank controls, the absorbance was used to normalise the fluorescence data from each 881 
well. 882 
Quantification of hydrogen sulfide levels using MitoA in vivo exomarker. MitoA and MitoN 883 
were quantified in mouse blood using LC-MS/MS. Mice received a tail vein IV injection of 50 884 
nM MitoA in 0.9% saline (100 μL). MitoA was given 1.5 hr to distribute into mitochondria. 885 
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Mice were culled by decapitation 90 minutes after administration. Liver was excised and flash 886 
frozen in liquid nitrogen. MitoA and MitoN were extracted from tissue by homogenization of 887 
liver (50 mg) enriched with 5 pg d15-MitoN (95% ACN, 210 μL) which was used as an internal 888 
standard (IS). Homogenates were centrifuged (16,000 g, 10 min, RT) and the supernatant was 889 
transferred to a clean tube and stored on ice. The pellet was re-extracted (95% CAN, 210 μL), 890 
spun down again (16,000 g, 10 min, rT) and the supernatants were combined and incubated 891 
at 4oC for 30 mins. Calibration standards comprise MitoA and MitoN standards ranging from 892 
0.01 to 10 pg in 500 μL 95% ACN. 500 μL of the supernatants and calibration standards were 893 
loaded onto an ISOLUTE PLD+ protein and phospholipid removal plate (Biotage, Sweden). 894 
Samples and standards were pulled through the plate under vacuum into a 2 mL deep-well 895 
96-well plate. Wells were dried completely at 40oC under N2 and resuspended in 100 uL 20% 896 
ACN, 0.1% FA. The plate was shaken at (250 rpm, 20 min) to ensure reconstitution. Liquid 897 
chromatography-Mass Spectrometry was performed on an I-class Acquity LC system-Xevo 898 
TQS triple quadrupole mass spectrometer (Waters, Warrington, UK). Samples were kept at 899 
10oC and injected onto an Acquity UPLC BEH C18 column fitted with a 0.2 μm filter (1 x 50 900 
mm, 1.7 μm, Waters). Chromatographic separation of MitoA and MitoN was achieved using 901 
mobile phase A composition: water:ACN, (95:5, 0.1% FA), mobile phase B: ACN:water (90:10, 902 
0.1% FA).  LC mobile phases were infused at 200 μL/min using the gradient: 0– 0.3 min, 5% B; 903 
0.3–3 min, 5–100% B; 3– 4 min, 100% B, 4.0– 4.10, 100–5% B; 4.10– 4.60 min, 5% B. MS/MS 904 
analysis was performed under positive ion mode (Source spray voltage, 3.2 kV; cone voltage, 905 
125 V; ion source temperature, 100 °C). Curtain and collision gas were nitrogen and argon, 906 
respectively. Analytes were detected by multiple reaction monitoring (MRM). MitoA 907 
undergoes neutral loss of N2 to a nitrene (precursor ion). For quantification the following 908 
transitions were used: MitoA, m/z 437.2 Æ183.1; MitoN, m/z 439.2 Æ 120.0; d15-MitoN, 909 
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454.2 Æ 177.1 m/z. MassLynx 4.1 software was used to integrate the peak area of the 910 
analytes MitoA, MitoN and the d15-MitoN internal standard. Response was calculated by 911 
normalizing sample peak areas to the IS peak area. By comparison of sample responses to 912 
calibration standard responses the mass of each analyte in the tissue sample was calculated. 913 
The mass of analyte was normalised to the mass of tissue homogenizer and MitoN/MitoA 914 
ratio was calculated. 915 
Preparation of hepatic mitochondria. Fresh liver was taken from mice, and homogenised in 916 
250 mM sucrose, 10 mM HEPES, 1 mM EGTA. 0.5% fatty acid free bovine serum albumin (BSA) 917 
pH 7.4 at 4°C, with seven passes of a loose glass Dounce homogeniser (Type A). Homogenates 918 
were centrifuged in glass tubes at 2900 rpm (1000 g) for 10 min in a pre-chilled 4°C Beckman 919 
centrifuge (JA-20 Fixed angle rotor). The supernatant was then centrifuged in glass tubes at 920 
8500 rpm (8700 g) for 10 min at 4°C. The supernatant was aspirated and any visible lipid was 921 
carefully removed from the sides of the tubes. The pellet was washed with 5 ml of mIR-05 922 
buffer (0.5 mM EGTA, 3 mM MgCl2, 20 mM taurine, 10 mM KH2PO4, 20 mM HEPES, 110 mM 923 
sucrose, 1 mg/ml fatty acid free BSA, pH 7.2), and centrifuged at 8500 rpm (8700 g) for 10 min 924 
at 4°C. After aspiration and removal of visible lipid, the pellet was suspended in 1ml of mIR-925 
05 buffer and kept on ice until used. All measurements were taken within two hours of 926 
preparation. Protein concentration was determined using the DC-Protein Assay (BioRad) as 927 
per manufacturers instruction. 928 
Amperometric analysis of sulfide disposal. Hepatocytes were prepared as described, and 929 
kept at room temperature in DMEM with 5.5 mM glucose, 10% FCS, 4 mM glutamax or 7 mM 930 
glutamine, and antibiotics at a concentration of 4 x 106 per ml. Mitochondria were prepared 931 
as described, and maintained on ice in mIR-05 buffer until use. All samples were analysed 932 
within 4 hours of preparation. Sulfide (H2S(g)) was measured (with and without samples) in a 933 
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2ml volume plastic chamber, to which an amperometric sensor was inserted, sealed with a 934 
rubber O-ring. Voltage measurements from the sensor (linear relationship to H2S(g) 935 
concentration) were recorded using a TBR4100 Gas radical analyser (World Precision 936 
Instruments). A gas permeable membrane covered the sensor, and the outer glass sensor 937 
compartment was filled with H2S detection fluid (World Precision Instruments). All 938 
measurements of H2S(g) from standards and samples were recorded as voltage by the 939 
amperometric sensor at ambient temperature. Mitochondrial measurements (and standards) 940 
were taken in serum free mIR-05 buffer. Hepatocyte measurements (and standards) were 941 
taken in serum-free, bicarbonate-free DMEM, buffered with 25 mM HEPES (pH 7.4), with 5 942 
mM glucose, 2 mM glutamax and 2 mM pyruvate. Sulfide was added to buffer in the form of 943 
Na2S, predicted to equilibriate according to its Pka at this pH to about 1/3 of sulfide as H2S(g) 944 
2/3 as HS-. The probes selectivity to H2S(g) (vs HS-) was confirmed with standards by 945 
demonstrating predicted signal amplification to a maximum following acidification of media 946 
to pH < 5 (approx. 100% H2S(g)/0% HS-), and signal compression to a minimum following 947 
alkalinisation of standard to pH > 10 (Approx 0% H2S(g)/100% HS-/S2-). A final re-acidification 948 
recovered the signal to near maximal levels. Standard curves for calculating experimental 949 
measurements were prepared using freshly made Na2S solutions ranging from 0.25 – 20 µM 950 
(corresponding to approximately 170 nm – 6.7 µM H2S(g)). H2S(g) disposal was measured by 951 
recording the extrapolated H2S(g) concentration after 10 min incubation with samples. A 952 
baseline without sample was taken for 5 min, and then after sample addition (400,000 953 
hepatocytes, or 1.6 – 2.0 mg of mitochondrial prep), another 5 min baseline with sample was 954 
taken. In all experiments, no detectable increase in signal (limit of detection 0.25 µM Na2S) 955 
was observed during incubation of hepatocyte or mitochondrial samples from either 956 
genotype. Following addition of 10 µM Na2S the (voltage) signal was recorded over a period 957 
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of 10 min. Disposal rates were calculated after subtraction of a baseline disposal rate in media 958 
alone, over a 10 min period, performed each day of experimentation. Sample disposal rates 959 
were in the range of 5-20 higher than baseline disposal rate confirming good signal to noise. 960 
To determine the rate of disposal that is dependent upon respiration, a fresh aliquot of the 961 
same sample was prepared as before, but 5 min after addition of sample to chamber, 962 
Antimycin A (2.5 µM, dose titrated) was added. After a further 5 minutes, 10 µM Na2S was 963 
added and a disposal rate (after subtraction to sample free baseline rate) was again 964 
calculated. The respiratory (Antimycin sensitive/complex III dependent) sulfide disposal rate 965 
of samples was calculated as the difference between the nieve sample rate and the Antimycin 966 
inhibited rate. After each measurement, the sample was removed, and centrifuged to collect 967 
cells or mitochondria for a final protein assessment (DC-Protein Assay, Bio-Rad) for the 968 
purposes of normalisation. 969 
Mitochondrial ROS (MitoSOX) measurement in H2O2 treated hepatocytes. Hepatocytes were 970 
seeded overnight onto 96-well collagen coated plates. Cells were exposed to a range of 971 
concentrations of H2O2 (0.125 - 8 µM) for 2 hours. Following 3 washes with PBS, cells were 972 
incubated with MitoSOX Red mitochondrial superoxide indicator (Thermo Fisher) for 10 mins 973 
prior to three further washes. Measurement of fluorescence was carried out in a fluorescence 974 
detector plate reader (TECAN), using 510 nm for excitation and 580 nm for emission 975 
detection. Data from each well was normalised to sulfurhodamine dye protein stain. 976 
Persulfidation Mass Spec and GO term analysis. Livers from mice were removed promptly 977 
following decapitation (within 2 min), and snap frozen in liquid nitrogen. The persulfide 978 
proteome analysis using the BTA method was conducted as described previously (Gao et al., 979 
2015). Briefly, 100-150 mg of frozen liver tissue was pulverized and lysed on ice in RIPA buffer  980 
(100 mM Tris, pH 7.5, 150 mM NaCl, 2mM EDTA, 1% Triton X-100, 25 mM deoxycholic acid, 2 981 
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tablets/ 100 ml of cOmplete™, Mini, EDTA-free Protease Inhibitor Cocktail (Roche)). The 982 
lysates were centrifuged at 14,000 g for 10 min at 4°C and protein concentrations were 983 
determined using the Bradford reagent (BioRad). Supernatant containing 6 mg of protein was 984 
incubated with 100 μM NEM-biotin (Pierce) for 60 min at room temperature after which the 985 
proteins were precipitated with cold acetone (1:4 v/v) for 1 h at -20°C, followed by a 986 
centrifugation at 14,000 g for 10 min at 4°C. The precipitated protein was re-suspended in a 987 
denaturing buffer containing 7 M urea, 1% SDS, 150 mM NaCl, 100 mM Tris, pH 7.5. Then, the 988 
samples were diluted 10-fold with trypsin reaction buffer (1 mM CaCl2, 100 mM Tris pH 7.5) 989 
and incubated overnight with sequencing grade modified trypsin (1:50 trypsin:protein) 990 
(Promega) at 30 °C. The digestion products were mixed with streptavidin-agarose beads 991 
(ThermoScientific) and incubated at 4° overnight, followed by ten washes with the wash 992 
buffer (0.1 % SDS, 100 mM Tris, pH 7.5, 600 mM NaCl, 1 mM EDTA, 1% Triton X-100). The 993 
streptavidin-agarose bound peptides were incubated with elution buffer (100 mM Tris, pH 994 
7.5, 150 mM NaCl, 1 mM EDTA, 30 mM DTT) for 1 hr at room temperature. Persulfidated 995 
peptides were eluted by centrifugation and derivatized with 40 mM iodoacetamide for 2 hrs 996 
at room temperature in the dark. The samples were then passed through a desalting column 997 
(Pierce). LC-MS/MS analysis was carried out using an LTQ-Orbitrap Elite mass spectrometer 998 
(Thermo-Fisher) coupled to an Ultimate 3000 high-performance liquid chromatography 999 
system. The alkylated peptides were loaded onto a 75 µm desalting column, C18 reverse 1000 
phase resin (Dionex), and eluted onto a Dionex 15 cm x 75 µm id Acclaim Pepmap C18, 2 μm, 1001 
100 Å reverse-phase chromatography column using a gradient of 2–80% buffer B (5% water, 1002 
95% acetonitrile, 0.1% formic acid) in buffer A (0.1% formic acid). The peptides were eluted 1003 
onto the mass spectrometer at a flow rate of 300 nl/min and the spray voltage was set to 1.9 1004 
kV. 1005 
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GO enrichment analysis. In order to identify differentially persulfidated proteins between the 1006 
C57Bl/6J and Tst—/— samples, we compared the abundances of persulfidated fragments in 1007 
appropriately treated mass spectrometry data sets to the estimated overall abundance of the 1008 
corresponding parent proteins in standard label-free quantitation experiments. For each 1009 
observed persulfidated fragment in each experimental replicate, we calculated the 1010 
persulfidation rate as the log2 ratio of the count of that persulfidated fragment to the median 1011 
count of that fragment across all experimental replicates. The observed counts for the Tst—/— 1012 
replicates were additionally scaled (prior to log transformation) by the ratio of abundances of 1013 
the parent protein between the C57Bl/6J and Tst—/— cells to normalize for differential protein 1014 
abundance across conditions. For each peptide we then assigned an approximate average 1015 
log2 fold change in persulfidation rate between the C57Bl/6J and Tst—/— conditions. If a 1016 
persulfidated peptide was identified in at least two biological replicates of one condition and 1017 
none in the other, we assigned a log2 fold change of +/- 5.0 as placeholder values indicating a 1018 
high confidence change; peptides with only one observation in one condition and none in the 1019 
other were omitted from our analysis. Having thus obtained estimates for the magnitude of 1020 
changes in persulfidation rate of each detectable peptide, we then performed gene ontology 1021 
term enrichment analysis using the estimated log2 fold changes. We consolidated the peptide-1022 
level data to protein-level data by taking the largest magnitude change in persulfidation levels 1023 
across all peptides from a given protein, and then used the iPAGE program 1024 
[http://dx.doi.org/10.1016/j.molcel.2009.11.016] to identify GO terms with significant 1025 
mutual information with the profile of persulfidation rates. Arguments to iPAGE were “—1026 
max_p=0.1 –minr=0.3 –ebins=9 –exptype=continuous”, indicated that the data were 1027 
discretized into nine equally populated bins prior to analysis, and that default hypergeometric 1028 
p-value and information content thresholds were relaxed to maximize sensitivity. 1029 
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Focussed analysis of persulfidation in gluconeogenesis proteins. The gluconeogenesis 1030 
pathway was selected for a focussed analysis of the persulfidation rate of all cysteine sites 1031 
detected in the mass spectrometry data as described above. All peptides from proteins 1032 
present in the persulfidation data set used for GO enrichment analysis, that are defined by 1033 
the GO term gluconeogenesis (GO 0006094) were included, these were Pgk1, Gpi1, Fbp1 and 1034 
Tpi1 (22 peptides). The log2 rate ratio of persulfidation (Tst—/— /6J) of all of these 22 peptides 1035 
was compared first to the entire mass spectrometry dataset for log2 rate ratio of 1036 
persulfidation (1245 peptides after removal of ambiguous peptides, peptides with a P-diff of 1037 
0, and the 22 gluconeogenesis peptides). A Mann-Whitney non parametric T-test was used to 1038 
detect significance. A second analysis was performed with the gluconeogenesis pathway. For 1039 
this analysis, all log2 rate ratio’s were given a positive sign to indicate the magnitude of change 1040 
in the Tst—/— relative to 6J, independent to the direction of change. A Mann-Whitney non 1041 
parametric T-test was then performed to determine if the magnitude of change in 1042 
persulfidation in the gluconeogenesis pathway was significantly higher than that of the overall 1043 
the data set.     1044 
Persulfidation labelling and western blotting from frozen liver. 80-120 mg of frozen liver 1045 
samples were homogenized on ice using a 2 ml glass Dounce homogenizer (Kimble), in 500 µl 1046 
buffer (7 M urea, 100 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1% 1047 
deoxycholic acid; supplemented with cOmplete Protease Inhibitor Cocktail (Roche)). Initial 1048 
disruption of tissue was achieved with three passes, using the loose (Type A) pestle, and after 1049 
5 min incubation on ice; complete homogenization was achieved with 9 passes using the tight 1050 
fit (Type B) pestle. Homogenates were centrifuged at 5000 rpm (2655 g) for 5 min at 4°C. 1051 
Protein concentrations of supernatants were determined using the DC BCA protein assay (Bio-1052 
Rad). Protein (6 mg) from each sample, was made up to 1 ml with phosphate buffered saline 1053 
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(pH 8.0). Freshly prepared EZ-link Maleimide PEG Biotin EZ-linker (Thermo Fisher 21902BID), 1054 
was added to samples to 100 µM, and incubated for 1 hour at room temperature with gentle 1055 
mixing. Excess maleimide linker was removed from samples by acetone precipitation (3 1056 
volumes) at -20°C for 1 h, followed by centrifugation at 12000 rpm (17390 g) for 10 min at 1057 
4°C. Protein pellets were washed with ice-cold acetone and then dissolved in 250 µl of 50 mM 1058 
Tris pH 8.0, 100 mM NaCl, 1 mM EDTA, 1 % SDS. To each sample, 750 µl of RIPA buffer (100 1059 
mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1% deoxycholic acid) was then 1060 
added. An aliquot (20 µl) was taken from each sample for estimation of total input protein for 1061 
normalization (described below). The remainder of the samples were split into duplicates and 1062 
incubated with gentle mixing, overnight at 4°C with 320 µl of pre-washed streptavidin agarose 1063 
beads (Thermo Fisher 20347). Beads were washed 10 times with 0.8 ml washing buffer (30 1064 
mM Tris pH 7.5, 600 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% SDS), followed by one wash 1065 
with phosphate buffered saline (pH 7.4). Beads were then centrifuged for 1 min at 1000 rpm 1066 
(106 g) to dry. Elution of the duplicate samples for western blot analysis was performed by 1067 
adding 300 µl of elution buffer (30 mM Tris pH 7.5, 150 mM NaCl). For each sample pair, one 1068 
duplicate was eluted in buffer supplemented with 10 mM DTT and the other without DTT. 1069 
The beads were incubated with the elution buffer for 1 hour at RT; and centrifuged for 1 min 1070 
at 1000 rpm (106 g) to collect the eluate. Each eluted sample was concentrated to 20 ul using 1071 
an Ultra-0.5 Centrifugal Filter Device, 10 K cut-off (Amicon), as per the manufacturer’s 1072 
instructions. Eluted samples, and input protein samples were loaded in their entirety onto 1073 
SDS PAGE gels and transferred overnight at 4°C by Western blotting onto PVDF membrane. 1074 
Total protein from each lane on the membrane was estimated after staining with REVERT 1075 
total protein stain (LICOR) according to the manufacturer’s instructions. Briefly, following 1076 
overnight transfer and after rinsing the blot with water, the membranes were incubated with 1077 
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REVERT total protein stain for 5 min, and rinsed twice with wash solution. Blots were then 1078 
imaged in the 700 nm channel with an Odyssey imaging system (LICOR). Each lane was 1079 
measured for its total integrated fluorescence intensity to obtain an estimate of the total 1080 
protein in each lane. Measurements from no-DTT eluted sample lanes were subtracted from 1081 
DTT eluted sample lanes. Similar fluorescence measurements of input total protein lanes 1082 
were used to normalise the eluted sample measurements, and this was used as a measure of 1083 
relative protein-persulfidation rate. 1084 
Mass spec analysis of liver protein. Sample preparation; Tst—/— and wild type (C57Bl/6J) 1085 
mouse strains were fed either high-fat (58% fat) or normal (low fat) diet. Livers from mice 1086 
were removed following decapitation, and snap frozen in liquid nitrogen. Four biological 1087 
replicates from the 4 conditions were used to isolated proteins and performed protein 1088 
quantitation using iTRAQ 8plex. Liver tissue was homogenized using 1 ml of 8 M urea with 1089 
HEPES buffer pH 8.0. The protein concentration was determined using the Bio-Rad RC DC 1090 
protein assay kit (Bio-Rad, Hercules, CA, USA). One hundred micro grams of protein from each 1091 
of the samples were reduced with THP (Tris(hydroxypropyl)phosphine), alkylated with MMTS 1092 
(methyl methanethiosulfonate) in 500 mM triethylammonium bicarbonate (TEAB, pH 8.5), 1093 
trypsin digested and subsequently label with iTRAQ 8plex accordingly to the manufacturer’s 1094 
instructions. Electrostatic Repulsion-Hydrophilic Interaction Chromatography (ERLIC) Peptide 1095 
fractionation; Peptide fractionation was performed using a pH gradient. Labeled peptides 1096 
were dissolved in 100 μL of buffer A (100 mM formic acid, 25% acetonitrile, pH 3.0), followed 1097 
by fractionation in a 2.6 × 200 mm, 5 Pm, 200 Å PolySulfoethyl A column (Poly LC Inc., 1098 
Columbia, MD), using an Ultimate 3000 UHPLC+ focused (Thermo-Fisher Scientific) system, 1099 
operating at a flow rate of 0.2 ml/min. Twenty minutes of isocratic buffer A were followed by 1100 
a linear gradient from 0% to 100% buffer B (100 mM ammonium formate, 25% acetonitrile, 1101 
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pH 6.0) over 20 min and then a final linear gradient from 0% to 100% buffer C (600 mM 1102 
ammonium acetate, 25% acetonitrile, pH 6.0) over 10 min. A total of 22 fractions (1-min 1103 
intervals) were collected. All fractions were lyophilized and stored at -20 °C. Nanoflow Liquid 1104 
Chromatography Tandem Mass Spectrometry; NanoLC MS/MS analysis was performed using 1105 
an on-line system consisting of a nano-pump UltiMate™ 3000 UHPLC binary HPLC system 1106 
(Dionex, ThermoFisher) coupled with Q-Exactive mass spectrometer (ThermoFisher, San Jose, 1107 
CA. iTRAQ-labeled peptides were resuspended in 2% ACN, 0.1% formic acid (20 μL) and 6 μL 1108 
injected into a pre-column 300 µm×5 mm (Acclaim PepMap, 5 µm particle size). After loading, 1109 
peptides were eluted to a capillary column 75 µm×50 cm (Acclaim Pepmap, 3 µm particle 1110 
size). Peptides were eluted into the MS, at a flow rate of 300 nL/min, using a 90 min gradient 1111 
from 0% to 35% mobile phase B. Mobile phase A was 2.5% acetonitrile with 0.1% formic acid 1112 
in H2O and mobile phase B was 90% acetonitrile with 0.025% trifluoroacetic acid and 0.1% 1113 
formic acid. The mass spectrometer was operated in data-dependent mode, with a single MS 1114 
scan in the orbitrap (400-2000 m/z at 70 000 resolution at 200 m/z in profile mode); automatic 1115 
gain control (AGC) was set to accumulate 4 × 105 ions, with a maximum injection time of 50 1116 
ms. MS/MS scans were performed in the orbitrap at 17 500 resolution. Ions selected for 1117 
MS/MS scan were fragmented using higher energy collision dissociation (HCD) at normalized 1118 
collision energy of 38% with an isolation window of 0.7 m/z. MS2 spectra were acquired with 1119 
a fixed first m/z of 100. The intensity threshold for fragmentation was set to 50 000 and 1120 
included charge states 2+ to 7+. A dynamic exclusion of 60 s was applied with a mass tolerance 1121 
of 10 ppm. Data Analysis; Raw files were converted to MGF files and searched against the 1122 
mouse UniProt database (81033 sequences, released on March 2014) using MASCOT Version 1123 
2.4 (Matrix Science Ltd, UK). Search parameters were peptide mass tolerance of 10 ppm, and 1124 
MS/MS tolerance of 0.05 amu allowing 2 missed cleavage. iTRAQ8plex (N-term) and 1125 
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iTRAQ8plex (K) were set as fixed modification, and acetyl (Protein N-term), Methylthio (C) and 1126 
Oxidation (M) were allowed as variable modification. Peptide assignments with ion score cut-1127 
off of 20 and a significance threshold of ρ <0.05 were exported to Excel for further analysis. 1128 
Data are available from the ProteomeXchange with identifier PXD028909. 1129 
GO and KEGG enrichment analysis of proteome data. The data generated from the initial 1130 
mass spectrometric analysis of iTRAQ labelled peptides from the 16 liver samples was 1131 
analysed by FIOS. A total of 16 samples were QC analysed using the arrayQualityMetrics 1132 
Bioconductor package to identify sub-standard and/or outlier samples. No samples were 1133 
identified as outliers. All samples passed the manual and automated quality control based on 1134 
three metrics (MAplot, Boxplot and Heatmap). The exploratory analysis using PCA showed 1135 
that the samples clustered perfectly into four groups based on the factor Group (representing 1136 
four genotype-diet combinations). The first PC captures the main source of variation in the 1137 
dataset and is showing a separation of the samples based on diet, where high-fat diet and 1138 
control diet samples separate. The second PC shows a separation between genotypes (Tst KO 1139 
and WT). The hierarchical clustering and PCA plot both show a clear separation based on the 1140 
iTRAQ labels. This is expected as the iTRAQ labels are confounded with the Groups. While the 1141 
observed separation of the samples into groups is most likely due to the underlying biological 1142 
differences, any technical variations (potentially introduced during the wet lab processing) 1143 
could be masked. The log2 ratio data were subsequently normalised within arrays using loess, 1144 
followed by normalisation between samples using the Gquantile method. A total of 4 single 1145 
and/or multi-factor comparisons, using statistical approaches, were performed. The contrast 1146 
"Tst KO vs WT mice (High-fat diet)" was analysed at a cut-off (unadjusted) p-value < 0.01. Due 1147 
to the known bias in fold-change magnitudes of the iTRAQ technology, no fold-change cut-off 1148 
was applied to the significant differentially abundant proteins. With this threshold 551 1149 
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proteins were differentially abundant in at least one of the comparisons. The contrast "High-1150 
fat diet vs Control diet (WT)" had the most DAPs (432) while the contrast " Tst—/— vs 6J mice 1151 
(High-fat diet)" had the least DAPs (83). Noticeably, the TST protein showed the strongest 1152 
down-regulation for both of the contrasts comparing Tst—/— to 6J mice, consistent with gene 1153 
deficiency and the fold change compression effect of iTRAQ. The full dataset (4,322 identified 1154 
proteins) was filtered to remove proteins having less than two detected peptides (on average 1155 
across all 16 samples); leaving 1,654 proteins for downstream analysis. Exploratory analysis 1156 
using principal component analysis (PCA) showed that the dataset separated into four distinct 1157 
groups based on the genotype-diet combinations along the two first principal components 1158 
(PCs). These 1,654 proteins were used for enrichment analysis for GO terms and KEGG 1159 
pathways. Individual proteins were considered of interest if they were found significantly 1160 
different (P < 0.01) between selected pairwise comparisons. The four comparisons were Tst—1161 
/— normal diet vs C57Bl/6J normal diet, C57Bl/6J high fat diet vs C57Bl/6J normal diet, Tst—/— 1162 
high fat diet vs Tst—/— normal diet, and Tst—/— high fat diet vs C57B/6J high fat diet. 1163 
Normalised mean abundance of proteins was expressed as Log2 fold change ratios for each 1164 
comparison.  1165 
Transcription factor enrichment analysis. 43 up-regulated proteins were selected for analysis 1166 
of their promoter sequences (selected on basis of P-value < 0.05; adjusted for comparison of 1167 
diet and genotype). 67 control proteins were selected from the proteome data on the basis 1168 
of their equivalence of abundance between C57Bl/6J and Tst—/—. We used a QIAGEN 1169 
hosted/SABiosciences mouse database (sabiosciences.com) of promoter located 1170 
transcription factor binding sites. 34 transcription factors were chosen to analyse, based on 1171 
either their a-priori prevalence in the promoter of Tst—/— up-regulated  proteins (present in 1172 
the promoters of more than 50% of the up-regulated proteins) or on their links to either 1173 
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sulfide or nutrient metabolism. The proportion of genes containing a TFBS was calculated for 1174 
the up-regulated set (43) and the control set (67). The ratio of up-regulated to control was 1175 
then calculated. The number of genes with and without the presence of the TFBS were 1176 
analysed for establishing statistical difference (Up-regulated vs Control), using a Fisher Exact 1177 
test (P < 0.05). 1178 
NRF2 target identification and proteome analysis. NRF2 target genes of the mouse liver were 1179 
compiled from the following reviews (Cuadrado et al., 2019, Tonelli et al., 2018, Rooney et 1180 
al., 2018, Walsh et al., 2014). 106 genes were identified as target genes (upregulated at mRNA 1181 
or protein level following NRF2 activation). 47 of these target genes were represented in our 1182 
liver proteome, and each protein was checked for relative expression between Tst—/— and 6J 1183 
(on normal diet, threshold of P < 0.01). 10 of the 47 target genes were lower in abundance in 1184 
the Tst—/— proteome, 37 unchanged, with none upregulated. To analyse whether this was 1185 
statistically significant, we compared this to the percentage of proteins upregulated, down-1186 
regulated or unchanged in the proteome database. 5.86% of proteins were upregulated, 1187 
5.62% downregulated, and 88.6% unchanged in the full database (1654 proteins total). 1188 
Expected (mean) numbers of proteins from a hypothetical set of 47 proteins, predict rounded 1189 
values of 3 upregulated, 3 downregulated and 42 unchanged. We used these as a reference 1190 
to the actual data for NRF2 target proteins; 0 upregulated, 10 downregulated and 37 1191 
unchanged. A Freeman-Halton Fisher Exact test was used for analysis of significance, and a 1192 
significant difference between predicted and actual distribution was found (PA = 0.039, PB = 1193 
0.047). 1194 
Electron micrograph imaging. Liver tissue for transmission electron microscopy was prepared 1195 
following immersion fixation in 0.1 M PB buffer (pH 7.4, EM-grade) containing 4% 1196 
paraformaldehyde and 2.5% glutaraldehyde. 1mm tissue blocks were post-fixed in 1% 1197 
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osmium tetroxide in 0.1 M PB for 45 min before dehydration through an ascending series of 1198 
ethanol solutions and propylene oxide. Tissue blocks were then embedded in Durcupan 1199 
before ultrathin sections (∼60/70 nm) were cut and collected on formvar-coated grids (Agar 1200 
Scientific, UK), stained with uranyl acetate and lead citrate in an LKB Ultrostainer and then 1201 
quantitatively assessed in a Philips CM12 transmission electron microscope (TEM).  1202 
Seahorse respiratory analysis. Primary hepatocytes (C57Bl/6J and Tst—/— mice) were seeded 1203 
immediately following purification onto collagen coated V7 Seahorse 24-well cell culture 1204 
microplates (Agilent Technologies), in 200 μl medium (DMEM, 5.5 mM glucose, 10% FCS, 7 1205 
mM glutamine, and penicillin/streptomycin antibiotics), for culture in a 5% CO2 37°C 1206 
incubator. Experiments were performed between 22-28 hours following collection from mice. 1207 
Optimisation experiments determined the optimal seeding density, which was then 1208 
standardised at 10,000/well. Optimisation for drugs and compounds used in Seahorse 1209 
experiments were performed separately with hepatocytes for each genotype and dietary 1210 
regime (normal or 58% high fat). This established the doses of drugs for respiratory 1211 
manipulation, which were the same for both genotypes and diets; oligomycin (2 μM), FCCP 1212 
(0.5 μM), and antimycin/rotenone (1 μM/0.2 μM). In all experiments, overnight media from 1213 
cells was replaced, after two washes (0.75 ml), with 525 μl of run media and incubated for 30 1214 
mins at 37°C (without CO2), prior to entry into the Seahorse XFe24 Extracellular Flux Analyser 1215 
(Agilent). The analyser was operated using Wave software (Agilent), and all oxygen 1216 
consumption rate (OCR) data was normalised to protein using the Sulforhodamine B stain 1217 
(described above). Data from each biological replicate was averaged from between 4-10 1218 
replicate wells, to produce a single value at each measurement time for each biological 1219 
replicate. Respiratory parameters were calculated as described below for each biological 1220 
replicate, and this data was used for statistical analysis of genotype effects. 1221 
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Mitochondrial stress test (MST). Run media for the MST was Seahorse assay media (Agilent), 1222 
supplemented with 10 mM glucose, 2 mM sodium pyruvate, pH 7.35 ± 0.5 at 37°C). Most 1223 
measurements were made using 3 min mixing, 2 min wait, 3 min measure. Measurements 1224 
following addition of FCCP to hepatocytes from high fat fed mice were measured using 4 min 1225 
mix, 2 min wait, 2 min measure. Three measurements were taken basally, and three 1226 
measurements taken after injection of each drug (in sequence; oligomycin for inhibiting ATP-1227 
linked respiration, FCCP for eliciting maximal uncoupled respiration, antimycin/rotenone for 1228 
inhibiting the respiratory electron chain). Respiratory parameters for each biological replicate 1229 
were calculated from the mean normalised OCR as follows. Basal respiration was calculated 1230 
by subtracting the third OCR measurement following injection of antimycin/rotenone (12th 1231 
measurement) from the third basal OCR measurement (3rd measurement). ATP linked 1232 
respiration was calculated by subtracting the third OCR measurement following the injection 1233 
of oligomycin (6th measurement) from the third basal OCR measurement (3rd measurement).  1234 
Maximum (uncoupled) respiration was calculated by subtracting the third OCR measurement 1235 
after injection of antimycin/rotenone (12th measurement) from the first measurement (peak 1236 
OCR) following injection of FCCP (7th measurement). Proton leak respiration was calculated 1237 
by subtracting the third OCR measurement after injection of antimycin/rotenone (12th 1238 
measurement) from the third measurement following the injection of oligomycin (6th 1239 
measurement). Non-respiratory OCR was taken from the third measurement after the 1240 
addition of antimycin/rotenone (12th measurement). 1241 
Octanoate rescue test. To investigate lipid respiratory metabolism, hepatocytes were 1242 
prepared, seeded and cultured overnight as above. Run media for the Octanoate rescue was 1243 
Seahorse assay media (Agilent), supplemented with 5 mM glucose, 0.1 mM sodium pyruvate, 1244 
1 mM sodium lactate, and 0.5 mM carnitine pH 7.35 ± 0.5 at 37°C). All measurements were 1245 
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made using 3 min mixing, 2 min wait, 3 min measure. After washing cells into run media, and 1246 
30 min before entry into the analyser, half of the wells from each genotype were incubated 1247 
with 8 μM etomoxir (or DMSO vehicle) to block carnitine dependent import of long chain fatty 1248 
acids into the mitochondria. Three basal measurements were taken prior to injection of 1249 
oligomycin, two measurements were taken prior to FCCP, two measurements were taken 1250 
prior to injection of sodium octanoate (250 μM), three measurements taken prior to 1251 
antimycin/rotenone followed by two final measurements. Standard respiratory parameters 1252 
were calculated analogous to the above description for the standard mitochondrial stress 1253 
test, except using the second measurement following injection of drug when only 2 1254 
measurements were taken. Dependency upon endogenous fatty acids for supporting 1255 
uncoupled respiration (Etomoxir inhibited respiration) was calculated for each biological 1256 
replicate using the maximal respiration prior to the addition of octanoate. Maximal 1257 
respiration was calculated as the 6th measurement (peak FCCP OCR) – 12th measurement 1258 
(lowest Antimycin/Rotenone OCR). The mean maximal respiration from the etomoxir treated 1259 
wells was subtracted from the mean maximal respiration of the vehicle treated wells to 1260 
calculate the Etomoxir inhibited respiration (long chain fatty acid dependency) for that 1261 
biological replicate. Octanoate stimulation of respiration (Octanoate stimulated respiration), 1262 
was calculated for each vehicle well by subtracting the second OCR measurement after 1263 
injection of FCCP (7th measurement) from the third measurement after injection of octanoate 1264 
(10th measurement).  1265 
Real time for mRNA analysis. RNA extraction, cDNA synthesis and real-time PCR were 1266 
performed as described (Morton et al., 2011, Moreno-Navarrete et al., 2013). Probes were 1267 
mouse Mpst, Mm00460389_m1, Tst, Mm00726109_m1; Gapdh (internal control), 1268 
Mm99999915_g1; and Tbp (internal control), Mm0000446973_m1.  1269 
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QUANTIFICATION AND STATISTICAL ANALYSIS 1270 
Quantification and Statistical Analysis. For analytes, bioenergetics, fluorescent probes, gene 1271 
expression, and protein levels, generally group sizes of 6 were calculated to allow detection 1272 
of differences in these variable parameters to a threshold of 15% (there is sufficient power to 1273 
detect smaller differences in certain parameters with this cohort size) with a power of at least 1274 
0.8. In some studies, limitations in animal numbers, or fewer remaining samples from larger 1275 
group sizes resulting from their use for multiple end-points, precluded the desired minimum 1276 
of n = 6 per group. Protein or mRNA differences in validation studies with 2 parameters (e.g. 1277 
diet with line or genotype) were analysed using 2-way ANOVA for line and diet effects 1278 
followed, where appropriate, by post-hoc Tukey tests or Holm-Sidak multiple comparison 1279 
tests using Sigmastat version 3.5 (Systat Software) or Prism (Graphpad Software). For simple 1280 
2 condition comparisons, t-test was used. For simple control versus treated (including 1281 
different treatments or concentration response curves) data were analysed by 1-way ANOVA. 1282 
For longitudinal measures (e.g. PTT, ITT, bodyweight gain) repeated measures (RM) ANOVA 1283 
was used and multiple comparisons determined. For all main in vivo studies, a blinding 1284 
strategy was used where the operator (e.g. for injections of glucose, or administration of drug) 1285 
was blind to the genotype of the subject during the experiment. Similarly, for analysis of 1286 
images (e.g. oil-red O staining) the scorer was blind to genotype and the data coded, with the 1287 
code broken by a second individual. Downstream analysis of e.g. tissue mRNA and protein 1288 
content was not generally blinded to allow appropriate data arrangement on e.g. 1289 
representative western blots. For clamp studies, mean ± standard error of mean (sem) will be 1290 
presented, statistical analysis will use t-test to investigate differences of genotype on each 1291 
diet (2 independent experiments, normal diet, and high fat diet, are not compared directly to 1292 
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each other). Statistical significance and the number (n) of subjects or samples for analysis are 1293 
indicated in the figure legends. 1294 
KEY RESOURCES TABLE 1295 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
Anti-TST                                                                         GeneTex                                        GTX114858 
Anti-MPST                                                     Abcam                                      ab224043 
Anti-GOT1                                                     Abcam                                      ab170950 
Anti-GSTT1                                                     Proteintech                    15838-1-AP 
Anti-MAT1A                                                     Abcam                                      ab129176 
Anti-BHMT                                                     Proteintech                    15965-1-AP 
Anti-CSAD                                                     Abcam                                      ab91016 
Anti-PPCS Atlas Antibodies HPA031361 
IRDye 800CW Goat anti-Rabbit LiCor 926-32211 
IRDye 680RD Donkey anti-Mouse LiCor 926-68072 
Anti-B-Actin Abcam ab8226 
Anti-CoxIV Abcam Ab16056 
Chemicals, peptides, and recombinant proteins 
sodium pyruvate 13C3  Sigma-Aldrich 490717 
Amyloglucosidase Roche ROAMYGLL 
Antimycin A Sigma-Aldrich A8674 
B-glycerophosphate Sigma-Aldrich G9422 
B-mercaptoethanol Sigma-Aldrich 444203 
Bovine serum albumin, essentially fatty acid free Sigma-Aldrich 10775835001 
Carbonyl cyanide-p-trifluoromethoxyphenylhydrazone 
(FCCP) 
Cayman Chemicals 15218 
Oligomycin A Cayman Chemicals 11342 
DL-Carnitine hydrochloride Sigma-Aldrich C9500 
Collagenase type 1 Worthington 
Laboratories 
LS004194 
cOmplete, Mini, EDTA-free Protease Inhibitor Cocktail Roche 11836153001 
Glucose, D-[3-3H]  PerkinElmer NET331C 
Deoxycholic acid Sigma-Aldrich D2510 
2’-deoxyguanosine 5’-diphosphate, sodium salt Sigma-Aldrich D9250 
Dithiothreitol Sigma-Aldrich 43816 
Durcupan ACM  Sigma-Aldrich 44610 
(+)- Etomoxir sodium salt hydrate Sigma-Aldrich E1905 
EZ-link Maleimide-PEG2-Biotin   Thermo Fisher 
Scientific 
21901BID 
Fetal Calf Serum, Brazilian Origin SLS Life Science HYC85 
Prestained Protein Marker Proteintech PL00001 
Glutamax Thermo Fisher 
Scientific 
35050061 
L-Glutamine Sigma-Aldrich G7513 
Glycine Sigma-Aldrich 50046 
Hematoxylin solution Abcam Ab220365 
Iodoacetamide Sigma-Aldrich I1149 
L-cysteine Sigma-Aldrich 30089 
Lead citrate, tribasic trihydrate Sigma-Aldrich 15326 
Malate dehydrogenase, porcine heart Sigma-Aldrich 442610-M 
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Skim Milk Powder Millipore 70166 
S-Methyl methanethiosulfonate Sigma-Aldrich 64306 
MitoSOX Red Mitochondrial superoxide indicator Thermo Fisher 
Scientific 
M36008 
NADH, Grade I disodium salt Roche 10107735001 
Pierce NEM (N-ethylmaleimide) Thermo Fisher 
Scientific 
23030 
Sodium octanoate Sigma-Aldrich C5038 
Oil Red O Sigma-Aldrich O0625 
Oligomycin A Sigma-Aldrich 75351 
Penicillin Streptomycin  Thermo Fisher 
Scientific 
15140122 
PERCOLL 8.5-9.5 Sigma-Aldrich P1644 
Phosphoenol pyruvate Roche 10108294001 
cOmplete protease cocktail inhibitor Roche 04693159001 
Rat tail collagen 1 Sigma-Aldrich 08-115 
REVERT total protein stain  LICOR 926-11011 
Rotenone Sigma-Aldrich R8875 
Sequencing grade modified Trypsin Promega V5111 
Sodium fluoride Sigma-Aldrich S7920 
Sodium L-lactate Sigma-Aldrich 71718 
Sodium orthovanadate Sigma-Aldrich 450243 
Sodium pyrophosphate Sigma-Aldrich 221368 
Sodium pyruvate Sigma-Aldrich P8574 
Sodium sulfate Sigma-Aldrich S9627 
Sodium thiosulfate Sigma-Aldrich 563188 
Sodium sulfide Sigma-Aldrich 407410 
Sulforhodamine B dye Sigma-Aldrich 230162 
Taurine Sigma-Aldrich 86329 
Tetrabutylammonium phosphate Sigma-Aldrich 86833 
Trichloroacetic acid Sigma-Aldrich T6399 
Triethylammonium bicarbonate Sigma-Aldrich 18597 
Trifluoracetic acid Sigma-Aldrich 80457 
Uranyl acetate Electron Microscopy 
Sciences 
22400 
Urea Sigma-Aldrich U5128 
XF Seahorse Base Media (DMEM) Agilent 102353-100 
14C-2-deoxyglucose                                               Perkin Elmer NEC495A 
4-(2-Hydroxyethyl)-1-piperazine                        
propanesulfonic acid 
Sigma-Aldrich                    1.15230 
2,4-nitrofluorobenzene                                       Sigma-Aldrich                    D1529 
Critical commercial assays 
Infinity Triglyceride Assay Thermo Fisher 
Scientific 
TR22421 
Infinity Cholesterol Assay Thermo Fisher 
Scientific 
TR13421 
Glucose Hexokinase Assay Abcam Ab136957 
iTRAQ reagent – 8PLEX Sigma-Aldrich 4281663 
Deposited data 
Proteome ProteomeXchange PXD028909 
Persulfidome ProteomeXchange PXD028909 
Experimental models: Cell lines 




Experimental models: Organisms/strains 
C57BL/6J (JAX mice strain) Charles River Strain code: 632 
Tst—/— C57Bl/6N mouse (backcrossed for >10 









Tst (mouse) FAM gene expression assay 4331182 Thermo Fisher Mm00726109_m1 
Mpst (mouse) FAM gene expression assay 4331182 Thermo Fisher Mm00460389_m1 
Gapdh (mouse) FAM gene expression assay 4331182 Thermo Fisher Mm99999915_g1 
Tbp (mouse) FAM gene expression assay 4331182 Thermo Fisher Mm0000446973_m1 
Software and algorithms 
Microsoft office   
Graph Pad Prism v8, 9 and 10   
Other 
Amersham Hybond P blotting membranes, PVDF Merck GE10600021 
Microvette CB300 K2E EDTA tubes Sarstedt 16.444.100 
Ultra-0.5 centrifugal filter, 10K cut off Millipore UFC501096 
Streptavidin-agarose beads Thermo Scientific 20347 
Formvar coated grids Agar Scientific AGS138 
Standard rodent diet SDS RM1 
Cornstarch diet Research Diets D12383 
58% High fat diet Research Diets D12331 
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SUPPLEMENTAL FIGURES and EXCEL TABLE; TITLES AND LEGENDS 1297 
Table S3 (Excel) 1298 
Table S3. Tst Deletion results in differential hepatic protein abundance of GO terms. Related to Table 1299 
3. (A) Significant GO terms represented by proteins that are more abundant in the ND-fed Tst—/— liver 1300 
compared with normal diet-fed C57Bl/6J. (B) Significant GO terms represented by proteins that are 1301 
less abundant in the ND-fed Tst—/— liver compared with normal diet-fed C57Bl/6J. ‘Genes’ indicates 1302 
the number of genes in the Tst—/— that represent the changes driving the GO term. The lists include 1303 
all regulated GO terms at a significance threshold of P < 0.05 1304 
  1305 
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A      TST mRNA in C57Bl/6J Pathways for deriving Isotopomers from 13C3 Pyruvate




















































































































































































D      Cell normalised total pool size of metabolites
Figure S1. Tst mRNA tissue expression profile in C57BL/6J mice and the metabolic
fates of 13C3 pyruvate in hepatocytes from Tst—/— mice. Related to Figure 1
Supplemental Text and Figures
Figure S1. Tst mRNA tissue expression profile in C57BL/6J mice and the metabolic fates of 13C3 pyruvate
in hepatocytes from Tst—/— mice. Related to Figure 1 (A) Histogram showing Tst mRNA level across liver,
colon, kidney, small intestine, skeletal muscle and epididymal fat from male C57BL/6J mice measured by
realtime-PCR and normalised to Tbp mRNA (B) Diagram representing metabolites derived from pyruvate.
Oxaloacetate was not detected but is indicated as an intermediate to production of malate or aspartate.
The isotopologue shown on the diagram represents to most abundant detected following pulse with 13C3
pyruvate. In red is the direction of change in hepatocytes of Tst—/— mice, with significance or P-values
(when less than 0.2) from t-tests. (C) Histogram showing isotopologues derived from 13C3 pyruvate from
C57Bl/6J (white bars, n = 5) and Tst—/— (red bars n = 4) cultured hepatocytes. Data represents the amount
of isotopologues detected by mass spectrometry, as a percentage of the total detected metabolite (total
includes unlabelled 12C and all detected 13C isotopologues). Counts were first normalised to cell number.
(D) Histograms showing the total pool size of each metabolite. Data is cell normalised mass spec counts
from all isotopologues of the given metabolite, including the relevant unlabelled 12C species. Data are
represented as mean ± SEM. Each metabolite was analysed using a t-test, ** indicates that P < 0.01. P-
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Figure S2. Insulin–regulated metabolic parameters in liver and plasma of Tst—/—
mice. Related to Figure 1. 
Figure S2. Insulin–regulated metabolic parameters in liver and plasma of Tst—/—
mice. Related to Figure 1. (A) Glycogen measured from whole liver from normal
diet-fed 4 hour fasted C57Bl/6J (6J; white bar, n = 5), and Tst—/— (red bar, n = 5)
mice. Data are represented as mean ±SEM. (B) Plasma glucose (mg/dl), over 120
minutes following insulin administration (i.p., 1mU/g) in normal diet-fed 4 hour
fasted C57Bl/6J (black line, n = 8) and Tst—/— (red line, n = 7) mice. (C) HPLC
quantified total plasma cholesterol in normal diet-fed 4 hour fasted C57Bl/6J
(white bar, n = 6) and Tst—/— (red bar, n = 6) mice. (D) HPLC quantified VLDL plasma
cholesterol in normal diet-fed 4 hour fasted C57Bl/6J (white bar, n = 6), and Tst—/—
(red bar, n = 6) mice. For (B) a Repeated Measures analysis demonstrated a
significant effect of time (****) and an interaction between time and genotype (*).
T-tests revealed that the decrement of glucose from baseline at 30 and 60 minutes
after insulin was greater in the Tst—/— (*).
A















Figure S3. Hepatocytes from Tst—/— mice resist hydrogen peroxide induced
mitochondrial reactive species accumulation. Related to Figure 2 and Table 1
Figure S3. Hepatocytes from Tst—/— mice resist hydrogen peroxide induced
mitochondrial reactive species accumulation. Related to Figure 2 and Table 1 (A)
Mitochondrial reactive oxygen species measured from primary hepatocytes by
MitoSox fluorescence from C57Bl/6J (white bars, n = 7) and Tst—/— (red bars, n = 7).
Cells were exposed to a range of doses of H2O2 prior to MitoSox incubation and
fluorescent detection. Data are represented as mean ±SEM. Significance was
calculated using 2-WAY ANOVA for H2O2 dose and genotype. A significant effect of
genotype is represented above the histogram with a *. H2O2 was significant to P <
0.001 (not represented on the histogram).



































ALL GLN ALL GLN
Figure S4. Persulfidation in the gluconeogenesis pathway is significantly different 
to global persulfidation patterns in the liver of the Tst–/–mice. Related to Figure 2 
and Table 3.
Figure S4. Persulfidation in the gluconeogenesis pathway is significantly different
to global persulfidation patterns in the liver of the Tst–/–mice. Related to Figure 1,
Figure 2 and Table 3. (A) Beeswarm plots showing the persulfidation log2 rate ratio
(Tst–/–divided by 6J) for peptides in the entire data set (ALL), alongside the log2 rate
ratio for peptides corresponding to proteins of gluconeogenesis (GLN). (B)
Beeswarm plots showing the magnitude of the log2 rate ratio (independent to
direction of change), for peptides in the entire data set (ALL), alongside the log2
rate ratios for peptides corresponding to proteins of gluconeogenesis (GLN). Data
are represented as individual peptide log2 rate ratio values, with the median
represented as a red line. Significance was calculated using the Mann-Whitney U
non parametric T-test. ** P < 0.01, **** P < 0.0001.
up–regulated down–regulated
A




















































































Figure S5. Validation of proteomic profiles by select western blot is exemplified by 
increased mitochondrial MPST. Related to Figure 3 and Table 3.
Figure S5. Validation of proteomic profiles by select western blot is exemplified by increased
mitochondrial MPST. Related to Figure 2 and Table 3. (A) Quantification of western blots for a
range of proteins found significantly up or down-regulated in the liver proteome of normal diet-
fed 4 hour fasted C57Bl/6J (6J; white bar, n = 4-6) and Tst—/— (red bar, n = 4-6) mice. (B)
Quantification of western blots for MPST from isolated liver mitochondria of normal diet-fed 4
hour fasted C57Bl/6J (white bar, n = 6), and Tst—/— (red bar, n = 6) mice. (C) Mpst mRNA
quantified by real time PCR from liver of normal diet-fed C57Bl/6J (6J; white bar, n = 6) and Tst—
/— (red bar, n = 6) mice. (D) Representative blots from LICOR imaging for the data quantified in
(A). Red arrow indicates where superfluous lanes have been removed to simplify visualisation
of genotype comparisons (GOT1, MAT1A, BHMT CSAD, mitochondrial MPST and COXIV). Data
are represented as mean ±SEM. Significance was calculated using un-paired two-tailed






















































































































A Transcription Factor Binding Sites in Promoters of Tst—/— up-regulated genes
NRF2 Target Proteins in the 
Tst—/— Liver
Figure S6. Hepatic proteins enriched in Tst—/—mice show under-
representation of NRF2 promoter binding sites. Related to Figure 3 and 
Table 3.
Figure S6. Hepatic proteins enriched in Tst —/— mice show under-
representation of NRF2 promoter binding sites. Related to Figure 3 and
Table 3. (A) abundance in Tst—/— liver compared to a control set of
proteins that are unchanged between 6J and Tst—/—. The proportion of
genes containing a promoter binding site from proteins increased in
Tst—/—was divided by the proportion of genes containing a binding site
from a control set of genes. (B) Pie charts representing the number of
NRF2-target proteins whose abundance is increased (blue), decreased
(yellow) or unchanged (grey) in the Tst-/- liver. Significance of
transcription factor enrichment analysis was calculated using a Fishers
Exact test. * P < 0.05. Significance for NRF2 target abundance was
performed with the Freeman-Halton Fishers Exact Test.
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Figure S7. Hepatocyte respiration after high–fat feeding or after amino acid or pyruvate challenge is 
comparable between C57Bl/6J and Tst–/– mice in vitro. Related to Figure 4. 
Figure S7. Hepatocyte respiration after high–fat feeding or after amino acid or pyruvate
challenge is comparable between C57Bl/6J and Tst–/–mice in vitro. Related to Figure 4. (A)
Maximal respiratory OCR elicited by uncoupling with FCCP, by hepatocytes from normal
diet-fed C57Bl/6J (n = 6) or Tst—/— (n = 6) mice, calculated from Figure 3B. (B) Non-
respiratory OCR remaining following the inhibition of respiration with antimycin and
rotenone, by hepatocytes from normal diet-fed C57Bl/6J (n = 6) or Tst—/— (n = 6) mice,
calculated from Figure 3B. (C) Seahorse trace representing the mean oxygen consumption
rate (OCR), normalised to protein, by hepatocytes from normal diet-fed (n = 6/genotype),
and high fat diet-fed (n = 4/genotype) C57Bl/6J and Tst—/—mice during a mitochondrial
stress test. (D)Basal respiratory OCR linked to ATP production (antimycin/rotenone
sensitive) by hepatocytes from high fat diet-fed C57Bl/6J (n = 4) or Tst—/— (n = 4) mice,
calculated from Figure S4C. (E) Respiratory OCR linked to ATP production (oligomycin
sensitive) by hepatocytes from high fat diet-fed C57Bl/6J (n = 4) or Tst—/— (n = 4) mice,
calculated from Figure S4C. (F) Respiratory OCR relating to proton leak (oligomycin
insensitive) by hepatocytes from high fat diet-fed C57Bl/6J (n = 4) or Tst—/— (n = 4) mice,
calculated from Figure S4C. (G) Maximal respiratory OCR elicited by uncoupling with FCCP,
by hepatocytes from high fat diet-fed C57Bl/6J (n = 4) or Tst—/— (n = 4) mice, calculated
from Figure S4C. (H) Non-respiratory OCR remaining following the inhibition of respiration
with antimycin and rotenone, by hepatocytes high fat diet-fed C57Bl/6J (n = 4) or Tst—/— (n
= 4) mice, calculated from Figure S4C. (I) Stimulation of maximal uncoupled respiration
following addition of pyruvate (2mM), from normal diet-fed C57Bl/6J (n = 4) or Tst—/— (n =
4) mice. (J) Stimulation of maximal uncoupled respiration following addition of aspartate
(1mM) and glutamax (1mM), by hepatocytes from normal diet-fed C57Bl/6J (n = 1) or Tst—
/— (n = 1) mice. Data are represented as mean ±SEM. Significance was calculated using an
unpaired two tailed, student’s t-test. * P < 0.05.
 
Table S1. Parameters during the euglycemic hyperinsulinemic clamp    
(A) Parameters during the basal (pre clamp) experiment (60-90 minutes post tracer)  
Parameter                                           6J chow             Tst—/—  chow             6J HFD              Tst—/— HFD        Genotype           Diet  
Fasted Glucose 60 min (mg/dl)  116.35± 14.93  135.72± 7.22  146.50± 3.89  167.13± 9.68  *  **  
Glycolysis (mg/kg/min)  11.63 ± 1.60  11.12 ± 0.62  12.89 ± 0.57  12.61 ± 0.62  ns   ns (0.09)  
Glycogen synthesis (mg/kg/min)  21.48 ± 2.06  19.02 ± 2.04  15.08 ± 2.76  16.28 ± 2.50  ns  ****  
(B) Measurements and parameters during the clamp experiment (160-210 minutes post tracer)  
 
Parameter                                           6J chow           Tst—/—  chow     Genotype (chow)          6J HFD             Tst—/— HFD    Genotype (HFD)  
Glucose 160 min (mg/dl)  108.0 ± 5.0  121.0 ± 10.1  ns  120.1± 3.7  125.6 ± 10.3  ns  
Glucose 170 min (mg/dl)  120.3 ± 6.4  129.8 ± 5.8  ns  118.1 ± 4.1  143.9 ± 14.0  ns (0.08)  
Glucose 180 min (mg/dl)  115.0 ± 5.5  125.5 ± 2.5  ns (0.08)  125.9 ± 2.9  126.7 ± 6.8  ns  
Glucose 190 min (mg/dl)  124.0 ± 1.0  131.0 ± 4.6  ns  121.5 ± 4.7  116.1 ± 3.7  ns  
Glucose 200 min (mg/dl)  121.0 ± 5.0  125.3 ± 5.8  ns  121.9 ± 3.0  115.7 ± 5.3  ns  
Glucose 210 min (mg/dl)  113.0 ± 7.8  123.5 ± 4.6  ns  119.4 ± 4.0  116.9 ± 2.7  ns  
Glucose IR 160-210 min (mg/kg/min)  84.9 ± 4.2  85.0 ± 2.6  ns  70.26 ± 4.83  69.95 ± 4.96  ns  
Glucose IR 160 (mg/kg/min)  82.3 ± 5.1  87.1 ± 3.2  ns  68.8 ± 4.2  68.9 ± 5.1  ns  
Glucose IR 170 (mg/kg/min)  85.2 ± 4.9  89.0 ± 3.0  ns  70.0 ± 5.1  74.6 ± 4.4  ns  
Glucose IR 180 (mg/kg/min)  84.7 ± 4.4  83.5 ± 4.2  ns  70.6 ± 5.1  70.7 ± 6.2  ns  
Glucose IR 190 (mg/kg/min)  85.2 ± 4.0  86.1 ± 2.1  ns  69.9 ± 4.8  69.1 ± 5.7  ns  
Glucose IR 200 (mg/kg/min)  85.2 ± 4.0  84.8 ± 2.4  ns  70.4 ± 4.7  71.2 ± 4.5  ns  
Glucose IR 210 (mg/kg/min)  85.2 ± 4.0  84.5 ± 2.4  ns  70.4 ± 4.7  71.2 ± 4.5  ns  
Turnover (mg/kg/min)  85.97 ± 3.52  94.50 ± 3.87  ns   73.61 ± 5.07  63.08 ± 7.10  ns  
Hepatic Glucose Prod. (mg/kg/min)  1.10 ± 5.31  9.92 ± 9.15  ns  3.326 ± 4.03  -6.83 ± 7.93  ns  
Glycolysis (mg/kg/min)  45.90 ± 2.218  48.37 ± 2.05  ns  42.85 ± 1.48  36.42 ± 4.62  ns (0.19)  
Glycogen synthesis (mg/kg/min)  40.06 ± 4.44  46.12 ± 2.68  ns  30.76 ± 5.36  26.66 ± 4.49  ns  
Integral Glucose (dpm.min/mg)  3.6e7 ± 1.4e6  2.95e7 ± 1.2e6  *  1.88e7 ± 1.4e6  1.7e7 ± 1.6e6  ns  
IWAT glucose utilization (ng/mg.min)             14.21 ± 4.05              18.62 ± 2.04                      ns  4.53 ± 1.07                   6.64 ± 1.00                 ns   
EWAT glucose utilization (ng/mg.min)             7.523 ± 4.39             7.21 ± 2.18                        ns  2.94 ± 0.56                   3.64 ± 0.39                ns   
VL glucose utilization (ng/mg.min)  33.77 ± 2.98  38.66 ± 1.70  ns (0.17)  49.65 ± 9.19  47.42 ± 9.19  ns  
EDL glucose utilization (ng/mg.min)  35.79 ± 11.09  40.86 ± 10.25  ns  68.79 ± 8.65  61.29 ± 11.80  ns  
Soleus glucose utilization (ng/mg.min)  99.85 ± 12.38  123.60 ± 13.90  ns (0.13)  220.8 ± 24.45  198.5 ± 32.92  ns  
Tibialis glucose utilization (ng/mg.min)  47.25 ± 7.22  53.67 ± 4.40  ns  74.39 ± 6.46  80.16 ± 6.09  ns  
Heart glucose utilization (ng/mg.min)  161.40 ± 7.65  198.00 ± 14.09  ns (0.13)  226.6 ± 51.01  262.5 ± 23.29  ns  
Liver glucose utilization (ng/mg.min)  3.53 ± 0.56  3.57 ± 0.63  ns  3.378 ± 0.39  3.58 ± 0.46  ns  
End Clamp Insulin (µU/ml)  133.6 ± 7.03  126.4 ± 5.06  ns  147.2 ± 9.4  124.4 ± 10.9  ns  
* P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001  
 
  
Table S1. Parameters during the euglycemic hyperinsulinemic clamp. Related to Figure 1. Metabolic 
parameters measured during continuous trace infusion but prior to clamp (A) and during maintenance of 
euglycemia and hyperinsulinemia (B) from C57Bl/6J (chow-fed, n = 3, hfd-fed, n = 8) and Tst—/— (chow-fed, n = 
6, hfd-fed, n = 7) mice. Data are represented as mean ±SEM. Significance for the basal experiment (A) was 
calculated using a 2-WAY ANOVA for genotype and diet. Significance for the clamp (B) was calculated for each 





 Table S2. Hydrogen sulfide disposal by hepatocytes and mitochondria (Amperometry)  
nmoles/min/mg protein  C57Bl/6J  Tst—/—  Significance  
Hepatocytes   3.88 +/- 0.095  4.15 +/- 0.345  ns  
Hepatocytes (Respiratory)  1.97 +/- 0.176  2.91 +/- 0.288  *  
Hepatocytes (Non-respiratory)  1.91 +/- 0.181  1.24 +/- 0.117  *  
Liver Mitochondria  0.65 +/- 0.095  1.23 +/- 0.129  *  
Liver Mitochondria (Respiratory)  0.26 +/- 0.060  0.50 +/- 0.080  *  
* P < 0.05  
 
  
Table S2. Tst deletion results in increased respiratory H2S disposal by hepatocytes. Related to 
Figure 2 and Table 1. H2S disposal rates (measured by gas selective amperometry following addition 
of 10 µM Na2S) of hepatocytes (n = 6/genotype), or isolated liver mitochondria (n = 7/genotype) of 
ND-fed C57Bl/6J and Tst—/—mice. Rates of H2S disposal were measured with and without respiratory 
inhibition following addition of Antimycin (2µM). Antimycin insensitive disposal rates are referred to 
as non-respiratory. The Antimycin sensitive disposal rates are referred to as respiratory. Data are 
represented as mean ±SEM. Significance was calculated using paired two-tailed student’s t-test. * P 


















    
  
Table S4. Sulfide metabolism proteins in liver proteome (Tst—/— vs C57Bl/6J, ND-fed)  
  Feature ID     Name           Fold Change         Significance  
Q3UW66  MPST    Mercaptopyruvate sulfurtrasferase   1.27   **  
Q8R086  SUOX    Sulfite Oxidase   1.06    Ns  
Q3UDS4  SQOR    Sulfide quinone reductase-like   1.06    Ns  
Q91WT9  CBS        Cystathionine beta-synthase   1.03    Ns  
Q9DCM0  ETHE1   Ethylmalonic encephalopathy 1   -1.01    Ns  
Q8VCNS  CTH       Cystathionine gamma-lyase   -1.02    Ns  
* Raw P < 0.05, ** Adjusted P < 0.05     
 
  
Table S4. Tst deletion selectively regulates MPST in the sulfide pathway of normal diet–fed mice. 
Related to Figure 3 and Table 3. Relative peptide abundance of proteins of the sulfide production and disposal 
pathway from the liver proteome of normal diet (ND) fed mice. ‘Fold Change’ indicates the relative abundance 
of the protein in Tst—/— relative to C57Bl/6J.      
  
Table S5. GO terms - Nutrient metabolism; reduced in ND Tst—/— liver 
(Tst—/— vs C57Bl/6J liver, ND-fed)  
 
 GO-ID  Name  Genes  Significance  
 
0006629  Lipid metabolic process  19   **  
0006631  Fatty acid beta-oxidation  7   **  
0003995  Acyl-CoA dehydrogenase activity  3   *  
0047617  Acyl-CoA hydrolase activity  2   *  
* P < 0.05, ** P < 0.01    
 
  
Table S5. Tst Deletion results in reduction of selective fatty acid specific GO terms. Related to Figure 
3 and Table 3. Significant GO terms (glucose or lipid related) represented by proteins that are less 
abundant in the ND-fed Tst—/— liver compared with ND-fed C57Bl/6J. ‘Genes’ indicates the number of 
genes in the Tst—/— that represent the changes driving the GO term.  
  
  
     
 
Table S6 Insulin regulated proteins in Tst—/— and C57Bl/6J mice  
(A) Abundance of peptides of insulin–induced proteins (Tst—/— vs C57Bl/6J, ND-fed)  
 
Feature ID                               Name                                                   Fold change                      Significance  
Q3UGT1   CPT1A   1.03  Ns  
P19096   FASN   -1.04  Ns  
Q3UDA8   CPT2   -1.05  Ns  
Q3V2G1   APOA1   -1.10  Ns  
Q5SVI5   GCK   -1.14  *  
(B)  Abundance of peptides of insulin–suppressed proteins (Tst—/— vs C57Bl/6J, ND-fed)  
Feature ID                Name                                                                          Fold change                     Significance  
QO5421  CYP2E1   1.13  **  
Q9D6M3  SLC25AA2   -1.03  Ns  
Q8CI37  PCK1   -1.09  Ns  
Q3UJ70  HMGCS1   -1.09  Ns  
O08601  MTTP   -1.20  **  
(C) Abundance of peptides of insulin–induced proteins (Tst—/— vs C57Bl/6J, High Fat-fed)  
Feature ID                Name                                                                          Fold change                     Significance  
Q3UGT1  CPT1A   1.03  Ns  
P19096  FASN   -1.04  Ns  
Q3UDA8  CPT2   -1.05  Ns  
Q3V2G1  APOA1   -1.1  Ns  
Q5SVI5  GCK   -1.14  *  
(D)  Abundance of peptides of insulin–suppressed proteins (Tst—/— vs C57Bl/6J, High Fat-fed)  
Feature ID                Name                                                                          Fold change                     Significance  
QO5421  CYP2E1  -1.05   Ns  
Q9D6M3  SLC25AA2  -1.01   Ns  
Q8CI37  PCK1  1.09   Ns  
Q3UJ70  HMGCS1  -1.04   Ns  
O08601  MTTP  1.09   *  
*  Raw P < 0.05, ** Adjusted P < 0.05  
 
  
Table S6. Proteins regulated by insulin are broadly comparable in expression between Tst—/— and  
C57Bl/6J. Related to Figure 3. Relative abundance in proteins that are known to be induced (A) or suppressed  
(B) by insulin in the liver, from the liver proteome of normal diet fed mice. ‘Fold Change’ indicates the relative 
abundance of the protein in Tst—/— relative to C57Bl/6J. Relative abundance in proteins that are known to be 
induced (C) or suppressed (D) by insulin in the liver, from the liver proteome of high fat diet fed mice. ‘Fold 
Change’ indicates the relative abundance of the protein in Tst—/— relative to C57Bl/6J.  
  
  
Table S7. KEGG pathways shared by high fat feeding and TST deletion   
 Entry  Name  Comparison  Significance  
A. Shared up-regulated pathways       
 00260  Glycine, serine and threonine metabolism  Tst—/— vs 6J  **  
    HFD vs ND  **  
B. Shared down-regulated pathways      
00980  Metabolism of xenobiotics by cytochrome P450  Tst—/— vs 6J  ****  
    HFD vs ND  *  
00982  Drug metabolism – cytochrome P450  Tst—/— vs 6J  ****  
    HFD vs ND  *  
04142  Lysosome  Tst—/— vs 6J  **  
    HFD vs ND  ****  
04390  Hippo signaling pathway  Tst—/— vs 6J  **  
    HFD vs ND  ****  
05215  Prostate cancer  Tst—/— vs 6J  **  
    HFD vs ND  *  
04024  cAMP signaling pathway  Tst—/— vs 6J  *  
    HFD vs 6J  *  
04141  Protein processing endoplasmic reticulum  Tst—/— vs 6J  *  
    HFD vs 6J  **  
05211  Renal cell carcinoma  Tst—/— vs 6J  *  
    HFD vs 6J  *  
04722  Neurotrophin signaling pathway  Tst—/— vs 6J  *  
    HFD vs 6J  *  
04110  Cell cycle  Tst—/— vs 6J  *  
    HFD vs 6J  **  
04918  Thyroid hormone synthesis  Tst—/— vs 6J  *  
    HFD vs 6J  ***  
04612  Antigen processing and presentation  Tst—/— vs 6J  *  
    HFD vs 6J  **  
* P < 0.05, ** P < 0.01, *** P < 0.001 **** P < 0.0001    
  
Table S7. KEGG Pathways shared by high fat feeding and TST deletion. Related to Figure 3. (A) KEGG 
pathways that are significantly up-regulated in the same direction by both high fat diet (HFD vs ND), and Tst 
deletion (Tst—/— vs C57Bl/6J). (B) KEGG pathways that are significantly down-regulated in the same direction by 
both high fat diet (HFD vs ND), and Tst deletion (Tst—/— vs C57Bl/6J). ‘Comparison’ indicates the two groups being 






Table S8. Effect of high fat feeding on sulfide pathway proteins (High fat diet vs ND-fed)  
Feature ID  Name  Fold change in 6J  Significance  Fold change in Tst—/—  Significance  
Q3UW66  MPST   1.35  **    1.15    *  
Q8R086  SUOX   1.21  **    1.23    **  
Q545S0  TST   1.19  Ns    n/a    n/a  
Q8VCNS  CTH   -1.04  Ns    -1.06    Ns  
Q9DCM0  ETHE1   -1.05   Ns    1.03    Ns  
Q3UDS4  SQOR   -1.08   Ns    1.01     Ns  
Q91WT9  CBS   -1.10  *    -1.06     Ns  
*  Raw P < 0.05, ** Adjusted P < 0.05   
 
  
Table S8. Effect of high fat feeding on the sulfide pathway of C57Bl/6J and Tst—/— mice. Related to  
Figure 3. Protein abundances of the sulfide production and disposal pathway from the liver proteome of 
C57Bl/6J and Tst—/— mice. ‘Fold Change’ indicates the relative abundance of the protein in high fat diet fed mice 




Table S9. Pathways in Tst—/— that are regulated oppositely to high fat feeding   
 Entry  Name  Comparison  Direction  
A                     KEGG Pathways      
00980  Metabolism of xenobiotics by cytochrome P450  Tst—/— vs 6J  Decreased  
    HFD vs ND  Increased  
00983  Drug metabolism – other enzymes  Tst—/— vs 6J  Decreased  
    HFD vs ND  Increased  
00053  Ascorbate and aldarate metabolism  Tst—/— vs 6J  Decreased  
    HFD vs ND  Increased  
00040  Pentose and glucoronate interconversions  Tst—/— vs 6J  Decreased  
    HFD vs ND  Increased  
00830  Retinol metabolism  Tst—/—  vs 6J  Decreased  
    HFD vs ND  Increased  
B                    GO Terms     
0006629  Lipid metabolic process  Tst—/— vs 6J  Decreased  
    HFD vs ND  Increased  
0006631  Fatty acid beta-oxidation  Tst—/— vs 6J  Decreased  
            HFD vs ND  Increased  
0003995  Acyl-CoA dehydrogenase activity  Tst—/— vs 6J  Decreased  
    HFD vs ND  Increased  
0047617  Acyl-CoA hydrolase activity  Tst—/— vs 6J  Decreased  




Table S9. KEGG pathways and GO terms that are regulated in the opposite direction by high fat 
feeding compared to Tst deletion. Related to Figure 3. (A) KEGG pathways that are regulated in the 
opposite direction by high fat diet (HFD-fed C57Bl/6J vs ND-fed C57Bl/6J), to Tst deletion (ND-fed Tst—/— vs 
C57Bl/6J). (B) GO terms that are regulated in the opposite direction by high fat diet (HFD-fed C57Bl/6J vs ND-fed 
C57Bl/6J), to Tst deletion (ND-fed Tst—/— vs C57Bl/6J). ‘Comparison’ Indicates the two groups being compared. 
‘Direction’ indicates whether the protein abundance is decreased or increased in the first group relative to the 
second.  
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